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S1 Mechanisms of chemical carcinogens: role in
human risk assessment
LL Smith
Zeneca Central Toxicology Laboratory, Zeneca, Alderley Park, Macclesfield,
SK10 4TJ, UK
The extrapolation to man of data generated in experimental
animals is the quintessence of toxicology. It is now generally
accepted that for many drugs, industrial chemicals or pesticides,
the most scientifically rational approach to establishing the likely
risk of cancer to man depends on an understanding of mechanism
of toxicity in experimental animals, combined with an apprecia-
tion of the relevant human biochemical and physiological path-
ways.
The drug, tamoxifen, is a genotoxic rat carcinogen which has a
favourable risk benefit profile in the treatment of breast cancer
patients. In order to establish whether the ability of this drug to
provoke liver cancer in rats is relevant to human population, a
through investigation of its mechanism of carcinogenicity in rats
has been undertaken. This analysis is of particular relevance for
the utility of this drug for medical indications other than the treat-
ment of breast cancer, and these studies, taken with many years of
clinical use of the drug, enable a comprehensive risk assessment to
be established.
The industrial solvent, methylene chloride, causes tumours in
mouse lung by a mechanism which is arguably qualitatively
different to humans. Certainly there are major quantitative differ-
ences in the metabolism of methylene between man and animals,
which greatly alter the likelihood that this solvent will present the
same hazard to different species.
A number of drugs, industrial chemicals and pesticides cause
peroxisome proliferation in the liver of rodents. This phenomenon
has long been linked with the formation of the liver tumours and as
the understanding of the mechanism of peroxisome proliferation
has developed, so has our appreciation of the differences between
human liver and the liver in those species which develop peroxi-
somes. It now appears highly unlikely that chemicals which
produce liver tumours solely through the formation of peroxisome
proliferation are likely to pose a risk of humans and this has
considerably altered the risk assessment paradigm for this class of
chemical.
These examples reinforce the assertion that the most meaningful
risk assessments for human toxicity depend on a comprehensive
understanding of the biochemical basis of mechanism of carcino-
genicity.
S2 Risk factors in alkylating agent carcinogenesis:
ménage à trois?
GP Margison1, AC Povey1,2 and PJ O’Connor1
1CRC Section of Genome Damage and Repair, Paterson Institute for Cancer
Research, Christie Hospital, Manchester M20 4BX, UK; 2School of
Epidemiology and Health Science, Medical School, University of Manchester,
Manchester M13 9PT, UK
Exposure, uptake, distribution and metabolic or spontaneous
activation of carcinogens are clearly required to generate the DNA
lesions that can give rise to malignant transformation. DNA
replication on an appropriately damaged template is obligatory for
instituting mutations, and DNA repair processes can prevent this,
but generally only if they operate before DNA replication. Recent
studies using alkylating agents in model systems reaffirm the
concept that whilst the detection and quantitation of specific DNA
lesions is one important aspect of risk assessment, DNA repair and
DNA replication must also be taken into consideration as these can
be overriding determinants of the frequency with which damaged
target cells undergo the events that result in malignant transfor-
mation.
Supported by the Cancer Research Campaign and MAFF.
S3 Regulation of p53 function
A Phillip1, S Bates1, M Kubbutat1, R Ludwig1, P Clarke2,
F Stott2, G Peters2 and K Vousden1
1ABL Basic Research Program, NCI-FCRDC, Frederick, MD 21702, USA;
2ICRF, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK
p53 is one of the most frequently mutated tumour suppressor
genes in human cancers, and loss of p53 function is thought to
contribute to the development of most human malignancies. Under
normal circumstances p53 is a short-lived protein which is main-
tained at very low levels. Activation of a p53 response is mediated,
at least in part, by stabilization of the protein and accumulation
within the cell. We have recently identified the cellular protein
Mdm2 as a regulator of p53 stability. Co-expression of Mdm2 with
p53 results in extremely rapid degradation of p53 through the
proteasome, and this degradative pathway may contribute to the
maintenance of low p53 levels in normal cells. Interestingly,
Mdm2 is transcriptionally activated by p53 and may therefore play
a role in controlling the extent and duration of the p53 response.
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Article no. bjoc.1999.0733Since p53 protein can be stabilized following DNA damage, it
seems likely that mechanisms which allow p53 to become resistant
to degradation by Mdm2 exist. Degradation depends on the inter-
action between p53 and Mdm2, and modifications such as
phosphorylation, which have been shown to regulate p53/Mdm2
binding, could also modulate p53 stability. However, there are
additional mechanisms for the control of p53 degradation and we
have shown that regions of both p53 and Mdm2 distinct from the
domains required for the interaction of the two proteins are also
required for degradation.
p53 can be activated by many diverse signals and stabilization
may occur through several mechanisms. In recent studies we have
identified p14ARF, which is expressed from the CDKN2A locus
which also encodes the p16INK4A protein, as a protein which can
inhibit Mdm2-targeted degradation of p53 and therefore allow
accumulation of the p53 protein. p14ARF binds to a region of Mdm2
distinct from the p53 binding domain and does not directly inter-
fere with the interaction of p53 with Mdm2. p14ARF can be
detected in a trimeric complex with Mdm2 and p53, and leads to
the stabilization of both p53 and Mdm2. Interestingly, p14ARF does
not appear to contribute to the activation of p53 in response to
DNA damage, but the observation that deregulated E2F1 expres-
sion strongly activates p14ARF expression indicates that p14ARF
participates in the activation of p53 in response to abnormal pro-
liferative signals.
This research was sponsored by the NCI, DHHS under contract
with ABL.
S4 Micronutrients prevent cancer and delay aging
BN Ames
University of California, Berkeley, CA 94720, USA
Approximately 40 micronutrients are required in the human diet.
Deficiency of vitamins folic acid, B12, B6, C, or E, or iron, sele-
nium, or zinc, mimics radiation in damaging DNA by causing
single- and double-strand breaks, or oxidative lesions, or both. The
percentage of the US population that is deficient for these eight
micronutrients ranges from 5% to 20% for each, and may
comprise in toto a considerable percentage of the US population.
Folate deficiency occurs in approximately 10% of the US popula-
tion, and in two small studies, nearly half of low income (mainly
African-American) elderly and adolescents. Folate deficiency is
shown to cause extensive incorporation of uracil into human DNA
(4 million/cell), leading to chromosomal breaks [1]. This mecha-
nism is the likely cause of the increased cancer risk and perhaps
cognitive defects in humans. Micronutrient deficiency may
explain why the quarter of the population that eats the fewest fruits
and vegetables (5 portions a day is advised) has about double the
cancer rate of the quarter that eats the most.
Aging appears to be in good part due to the oxidants produced
as by-products of normal metabolism by mitochondria [2,3]. In old
rats mitochondrial membrane potential, cardiolipin levels, respira-
tory control ratio and overall cellular O2 consumption declines,
and the level of oxidants (per unit O2) increases [2]. The effective-
ness of the normal mitochondrial metabolites (conditional
micronutrients) acetyl carnitine and lipoic acid in restoring these
functions (when fed to old rats for a few weeks) to the level of a
young rat and apparently rejuvenating the rats [4] suggests a plaus-
ible mechanism. Oxidative damage [3] to proteins (the level of
oxidized proteins increases with age) and to lipid membranes
causes a deformation of structure of key enzymes, with a conse-
quent lessening of affinity (Km) for the enzyme’s substrate or coen-
zyme. Thus increasing levels of the substrate might restore the
Vmax of the enzyme, and thus normal function.
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S5 Tamoxifen, a carcinogen and chemopreventive
agent
DH Phillips1, W Davis1, A Hewer1, MR Osborne1,
PL Carmichael2 and HR Glatt 3
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Tamoxifen is a non-steroidal antioestrogen widely used in the
treatment of breast cancer. Preliminary results from a US chemo-
prevention trial indicate that it prevents breast cancer in some
high-risk women, but this effect has not been seen so far in
European trials. It is also a potent liver carcinogen in rats and
causes endometrial cancer in women. Understanding the mecha-
nisms of these effects is important for assessing the long-term risks
of tamoxifen and of its analogues. Tamoxifen has many properties
of a genotoxic carcinogen, including formation of covalent DNA
adducts in rat liver in vivo and in rat hepatocytes in vitro, but it
does not form DNA adducts in human hepatocytes. The metabolite
(-hydroxytamoxifen forms the same pattern of adducts as does
tamoxifen in rat liver cells, indicating that it is an intermediate in
the activation pathway. The major DNA adduct formed in liver
is chromatographically indistinguishable from the major product
of the reaction of a-acetoxytamoxifen with DNA, (E)-(-(N2-
deoxyguanosinyl)tamoxifen. Minor adducts are the cis-isomer of
this and analogous cis-and trans-substitution at the N6-position of
adenine. Metabolism studies in cell lines expressing different CYP
isoforms indicate that a-hydroxylation is carried out primarily by
the CYP3A family. In rat hepatocytes, activation of both tamox-
ifen and a-hydroxytamoxifen to DNA binding products is highly
dependent on sulphate, being tenfold higher in medium containing
10 mM sulphate than in sulphate-free medium, and inhibited by
80% by dehydroisoandrosterone-3-sulphate. We expressed rat
hydroxysteroid sulphotransferase (hST) a (a liver-specific
enzyme) and human sulphotransferases (STs) in bacteria (S.
typhimurium) and in a mammalian cell line (V79 cells) and tested
a-hydroxytamoxifen for DNA adduct formation and mutagenicity,
using unmodified cells as controls. In cells expressing rat hST, a-
hydroxytamoxifen was mutagenic and formed the same DNA
adduct pattern as that found in the liver of tamoxifen-treated rats.
a-Hydroxytamoxifen was not activated in cells expressing human
STs. This mechanism provides an explanation for interspecies
differences in tamoxifen carcinogenicity and suggests that the risk
of DNA adduct formation (and cancer) in the human liver is low. It
explains why tamoxifen is a powerful carcinogen in rat liver, and
why standard short-term tests fail to detect its mutagenicity.
Tamoxifen does not form significant levels of adducts in human
endometrium or white blood cells.
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P Burns
Molecular Oncology, Department of Pathological Sciences, Algernon Firth
Building, University of Leeds, Leeds LS2 9JT, UK
Genotoxic agents leave their stigmata on genetic material in the
form of alterations in DNA sequence. The best place to look for
these in human tumours is the p53 gene. A large and invaluable
database of > 10 000 p53 mutations from most types of human
malignancy have been collected at IARC. The p53 mutational
landscape found in each tumour-type is the end-product of a
number of processes including initial interaction between agent
and DNA, repair, polymerase fidelity and biological selection.
DNA sequence context has a profound influence on each of these
factors. In order to investigate the contribution of putative carcino-
gens to human carcinogenesis it is advantageous therefore to use
the human p53 gene as a mutational target. In order to fulfil this
requirement we have modified Richard Iggo’s yeast-based p53
functional assay for use as a p53 forward mutation assay.
However, problems arise when studying mutational landscapes
even when using the most appropriate human target gene as a
window. With few exceptions, such as skin cancer and some occu-
pational exposures, the aetiology of cancer is invariably complex.
What is the likelihood that we will be able to dissect out the
different contributions made to mutational landscapes by multiple
agents in a scenario involving complex exposures? This presenta-
tion will describe our attempts to understand cancer aetiology by
analysing the p53 mutational spectra generated by a number of
well-characterized human carcinogens.
S7 Inducible expression of antioxidant and
detoxication enzymes as a mechanism of cancer
chemoprevention
JD Hayes1, MM Manson2, GE Neal2 and A Gallina3
1Biomedical Research Centre, UK Ninewells Hospital and Medical School,
University of Dundee, Dundee DD1 9SY, UK; 2MRC Toxicology Unit,
University of Leicester, Leicester LE1 9HN, UK; 3Consiglio Nazionale delle
Ricerche, Via Abbiategrasso 207, I-27100 Pavia, Italy
There is strong epidemiological evidence that certain forms of
cancer can be prevented by dietary intervention, specifically by the
high intake of fruit and vegetables. The mechanism whereby diet
can protect against carcinogenesis is controversial. It has been
proposed that phytochemicals are metabolized within the cell to
pro-oxidant species which, in turn, induce the expression of genes
that effect adaptive responses to harmful genotoxic agents.
Alternatively, it has been suggested that phytochemicals serve to
overcome inhibition of apoptosis, thereby allowing the selective
removal of damaged and mutated cells. Both induction of detoxi-
cation enzymes and modulation of apoptosis are probably impor-
tant in chemoprevention, and are possibly interdependent.
Our laboratories have investigated the mechanisms of chemo-
prevention against aflatoxin B1 hepatocarcinogenesis in the rat,
and have identified glutathione S-transferase (GST) A5 and
aldoketo reductase 7 (AFAR) as highly inducible cytosolic detoxi-
cation enzymes that metabolize the mycotoxin. These enzymes
have proved to be induced by structurally-diverse chemicals
including phenolic antioxidants, isothiocyanates, indoles and
lactams. Immunohistochemistry has revealed that the zone of the
liver where enzyme induction occurs varies with the agent
employed. Moreover, treatment with chemopreventive agent was
found to result frequently in nuclear translocation of GST.
Immunofluorescence microscopy has shown that AFAR can asso-
ciate with the Golgi apparatus. Thus, evidence suggests that both
GST and AFAR are represented in other subcellular compartments
besides the cytoplasm where they are assumed to have additional
functions besides that of drug metabolism.
Transcriptional activation of GST genes occurs through the
antioxidant responsive element (ARE; 5¢-TGACnnnGCA-3¢).
Work by Yamamoto and his colleagues, using a knockout mouse,
has demonstrated that the Nuclear-factor-erythroid 2-related factor
2 (Nrf2) mediates GST induction by butylated hydroxyanisole.
Studies are underway to determine whether Nrf2 mediates induc-
tion by all chemopreventive blocking agents.
S8 Gene–environment interactions for cancer risk and
behaviour
PG Shields
Molecular Epidemiology Section, Laboratory of Human Carcinogenesis,
Division of Basic Sciences, National Cancer Institute, Building 37, Room
2C16, Bethesda, MD 20892, USA
Molecular epidemiology methods emphasize a priori mechanistic
hypotheses and uses biomarkers to explore causative relationships.
The goal is to improve risk assessment (both population- and indi-
vidual-based), elucidate carcinogenic mechanisms and enhance
cancer prevention methods. Scientific methods, in general, tend to
assume that the population is homogeneous, whether the study
relates to a single cloned gene or the study of means in a popula-
tion. However, the human genome is highly complex and diverse
among individuals. One of our fundamental questions is why only
one in ten heavy smokers suffer from lung cancer. These methods
have allowed us to establish that gene–environment interactions
exist, where one’s genes can modify the effect of carcinogen expo-
sure. For this presentation, I will focus on our recent studies of
breast cancer, tobacco smoking, oxidative damage and diet. I also
will discuss recent studies for gene–neurobehavioural risk factors
for tobacco addiction.
S9 The potential for cancer prevention by dietary
factors: the role of selenium and flavonoids
PR Harrison
The Beatson Institute for Cancer Research, CRC Beatson Laboratories,
Glasgow G61 1BD, UK
It is generally acknowledged that the diet is a significant factor
affecting cancer risk and, in particular, that diets rich in fruits and
vegetables are associated with a lower risk of many cancers. It is
therefore important to identify which dietary factors contribute to
this protective effect and elucidate their mechanisms of action,
since this might suggest ways to help to protect high-risk groups
and lead to the development of synthetic analogues which might
be effective chemopreventive agents. This talk will review our
group’s recent work concerning the potential of flavonoids and
selenium compounds as cancer-protective agents.
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agents
MM Manson, A Gescher, EA Hudson and SM Plummer
MRC Toxicology Unit, University of Leicester, LE1 9HN, UK
Epidemiological studies have long suggested that diet can exert
both a negative and a positive effect on health. In particular, diets
rich in fresh fruit and vegetables have been shown to be protective
against cancer in a variety of target tissues. In addition, beneficial
effects of plant and herb extracts have been exploited over the
centuries in various forms of medicine. It is now apparent that
there are dozens of individual non-nutritive components in food
which can exert profound effects on the biochemistry and physi-
ology of cells with which they come in contact. Historically, the
effects of chemopreventive agents have been divided into those
which block and those which suppress the formation of cancer.
Blocking mechanisms prevent carcinogen–DNA interaction by
altering activation of the carcinogen or enhancing its conjugation
and excretion. They include alterations to phase I (cytochrome
P450s) and phase II drug metabolizing enzymes (e.g. glutathione
S-transferases, aldehyde reductase, quinone reductase, UDP-
glucuronyl transferase, epoxide hydratase) as well as induction of
DNA repair capacity. Suppressing mechanisms inhibit promotion
and progression of cancer by inhibiting cell proliferation and
increasing apoptosis. They can achieve this by modulation of
signal transduction pathways and altered transcriptional regula-
tion. Many chemopreventive agents appear to have more than one
mechanism of action. The potential role of several such agents,
including indole-3-carbinol (from cruciferous vegetables), epigal-
locatechin gallate (from green tea) and curcumin (from turmeric),
in blocking and suppressing carcinogenesis will be discussed.
S11 Chemoprevention of colon cancer: diet NSAIDs
and apoptosis
C Paraskeva, A Hague, T Crew and DJE Elder
Department of Pathology and Microbiology, School of Medical Sciences,
University of Bristol, University Walk, Bristol BS8 1TD, UK
Colorectal cancer continues to be a major cause of cancer deaths in
much of the industrialized world. A number of the genetic changes
which occur during colorectal carcinogenesis are thought to
uncouple proliferation, differentiation and apoptosis (programmed
cell death). The reactivation of apoptosis is thought to be impor-
tant in the chemoprevention and treatment of colorectal cancer.
There is increasing clinical, epidemiological and experimental
evidence that dietary and pharmacological intervention may
dramatically reduce the incidence and number of colorectal cancer
deaths. We have previously reported that butyrate (a fermentation
product of dietary fibre/resistant starches) induces apoptosis in
colorectal tumour cell lines and that the induction of apoptosis
may be part of the chemopreventive action of dietary fibre.
Humans who take NSAIDs (non-steroidal anti-inflammatory
drugs) on a regular basis have a 40–50% reduction in the relative
risk of colorectal cancer. Interestingly, it has also been shown that
the traditional NSAIDs and their derivatives (e.g. salicylate,
sulindac) induce apoptosis in colorectal tumour cells, suggesting
the induction of apoptosis to be a common mechanism for chemo-
preventive agents. However, the use of traditional NSAIDs –
which inhibit both forms of cyclooxygenase (COX-1 and COX-2),
a key enzyme in the synthesis of prostaglandins from arachidonic
acid – has been restricted because of their gastrointestinal toxicity.
A new class of aspirin-like drugs, the so called COX-2 selective
NSAIDs which are not as toxic have been developed. These COX-
2 selective inhibitors in experimental studies retain much of the
chemopreventive activity of the traditional NSAIDs raising the
exciting possibility that they could be used to reduce the incidence
of bowel cancer in the general population. Recent progress in the
mechanism(s) by which dietary factors and NSAIDs are thought to
be protective and the possible interactions between diet and phar-
macological agents will be reviewed.
S12 Chemoprevention by diet
S Bingham
MRC Dunn Nutrition Unit, Hills Road, Cambridge CB2 2DH, UK
Epidemiological estimates suggest that up to 80% of this breast,
bowel and prostate cancer is attributable to diet, which means that
it is a potentially preventable disease. However, most of the
epidemiological evidence has been derived from prospective
studies using simple methods to assess dietary exposure so that
estimates of relative risk relate to foods, rather than specific nutri-
ents. High levels of meat, and low levels of vegetables, starch and
non-starch polysaccharides (NSP) are associated with higher risk,
and there are plausible mechanisms whereby somatic mutations
which are relevant to current genetic models of cancer could be
initiated or not repaired by factors in these foods, such as endo-
genous N-nitrosation, heterocyclic amines, ammonia and butyrate
formation, and the wide range of potential chemopreventive
agents in vegetables. These include phyto-oestrogens which are
currently thought to have both oestrogenic and anti-oestrogenic
effects at different sites. Whilst various trials of specific food
items have been set up, intervention trials of changes in dietary
patterns to assess effects on cancer incidence are not at present
being conducted.
S13 Evidence-based chemoprevention: a dream for the
future?
H Vainio
Institute of Environmental Medicine, Karolinska Institute, Box 210, S-171 77
Stockholm, Sweden
Numerous observational studies conducted during the late 1970s
and 1980s found inverse associations between estimated intakes of
vitamin A (retinol) and b-carotene and the risk of developing
cancer at various sites and other chronic diseases. However, two
recent intervention trials indicate that b-carotene supplements
potentially increase lung cancer incidence in smokers and in
asbestos-exposed workers, and increase mortality from cardio-
vascular disease. Consequently, many have questioned the value
of this whole approach of cancer chemoprevention. Is this an
adequate argument, or are we in danger of throwing the baby with
the bath water? The reductionism in which the current molecular
medicine paradigm has its roots tends to discourage investigators
from tackling the complex problems of interfering with tumour
development in vivo in humans (preventive trials) or in relevant
animal models. It is hard to evaluate how much effect the intense
debate about the disappointing results of the b-carotene trials has
done to reinforce this, but it is clear that the cost and the difficulty
of the human intervention trials have become an increasing
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trials in humans that the final truth about the biological effects of
tentative chemopreventive agents are obtained and the problems of
disease biology and systemic toxicity can be adequately addressed.
The current fashion in molecular oncology is directed too strongly
towards repetitive low-risk artificial in vitro systems. The inter-
vention trials with b-carotene produced data which could not have
been obtained otherwise; now it is the challenge for the scientific
community to clarify the apparent inconsistency between the trial
and observational data. Another challenge the oncology commu-
nity faces is how to support and encourage new models of chemo-
prevention in animals and in humans alike, buttressed by an
underlying mechanistic understanding of the complex process of
carcinogenesis.
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cells
CE Mothersill1, CB Seymour1, SA Lorrimore2 and 
EG Wright 3
1Radiation Science Centre, Dublin Institute of Technology, Kevin Street,
Dublin, Ireland, 2Radiation and Genome Stability Unit, Medical Research
Council, Chilton, Didcot, UK
A major challenge facing radiation protection research is to define
the population of cells at risk of surviving with damage. Since
there is a large body of evidence that genetic factors are important
in determining response to radiation, there is little point in trying
to study this in cell lines or inbred mouse strains unless these are
selected specifically for their different responses and used only to
give pointers to possible mechanisms. Otherwise the genetic vari-
ation underlying the variation in human responses, so essential to
developing radiation protection actions, will be lost. In an attempt
to assess human variation, scores of apoptosis, necrosis and induc-
tion of a wide range of proteins were made in primary explant
cultures of human normal urothelium and correlated with growth
post-exposure to a range of doses of cobalt 60. These data were
validated by similar experiments using CBA/H and C57/BL6
mouse strains, known to exhibit genetically determined differ-
ences in responses to radiation. The data for human tissues show a
wide variation in response with three broad categories being
identifiable. The commonest (approx. 60%) had a hypersensitive
response involving considerable apoptosis in the low dose region,
followed by ‘induction’ of a survival response at higher doses
involving the persistence of abnormal cells and a pattern of gene
expression consistent with suppression of apoptosis. The second
category (approx. 38%) showed no induction of the survival. The
rarest category showed an extremely hypersensitive low dose
response followed by induction of a survival response which was
also dose-dependent. In the mouse experiments, CBA/H (mice
known to be genetically unstable post-irradiation), had lower
levels of delayed cell death and apoptosis than C57/BL6 mice
(which are more stable). It is concluded that there is a variation in
response to radiation between human patient cultures, which is
detectable in this system and which is consistent with a pattern of
radiation induced delayed death/apoptosis correlating with long-
term genomic stability. The mouse experiments demonstrate the
importance of genetic factors in determining these responses.
1.2 Tamoxifen induces endometrial and vaginal cancer
in rats in the absence of endometrial hyperplasia
P Carthew, LL Smith, RE Edwards and BM Nolan
MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester
LE1 9HN, UK
Much controversy has surrounded the finding of an increased risk
of endometrial cancer in post-menopausal women taking tamox-
ifen as an adjuvant therapy for breast cancer (Fornander et al,
1993). The current explanation for this is that tamoxifen acts as an
agonist of oestrogen action in the uterus, leading to hyperplasia of
the endometrium, and thus promotes endogenous initiated cells to
neoplasias, as with hormone replacement therapy (Paganinihill et
al, 1969).
We have administered tamoxifen to neonatal rats on days 2–5
after birth, and produced a significant increase in the incidence
(26%) of uterine adenocarcinomas, along with a 9% incidence of
squamous cell carcinomas of the vagina in the absence of any
agonist effect. This demonstrates that an oestrogen agonist effect is
not an absolute requirement for the carcinogenic effect of tamox-
ifen in the reproductive tract of the rat. This does not substantiate
the hypothesis that the unopposed oestrogen agonist effect of
tamoxifen on the endometrium is responsible for the development
of endometrial cancers. The alternatives are that tamoxifen is
causing these cancers by its genotoxicity, even though this has
been difficult to detect in women or rats (Hemminki et al, 1996;
Carmichael et al, 1998); or that modification of ‘imprinted’
responses, due to tamoxifen treatment, cause reproductive tract
cancers to arise at a later time, in the same way as has been
proposed for diethylstilboestrol (McLachlan et al, 1998).
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1.3 Relative susceptibility of intestinal polyps vs
normal mucosa to genotoxic injury from
benzo[a]pyrene (BaP)
A Sattar1, DH Phillips2, A Hewer3 and FC Campbell1
1Department of Surgery, University of Newcastle, UK; 2Institute for Cancer
Research, Sutton, UK
Intestinal cancers arise through stepwise genotoxic or mutational
damage, in polyps. Polyp capacity for carcinogen metabolism may
influence genotoxic injury, but data are lacking. We test the
hypothesis that polyps have different metabolic capacity and
susceptibility to genotoxic injury, than normal mucosa.
Expression of bioactivation (cytochrome (CYP) p4501A1/1A2)
and detoxification enzymes (glutathione S-transferases (GST) a, m
and p class) were assessed in polyps and normal intestinal mucosa
from APCmin mice, before and 48 h after in vivo exposure to
benzo[a]pyrene (100 mg kg–1). BaP:DNA adducts were assessed
by 32P post-labelling, in polyps and normal mucosa from APCmin
intestines.
Eighty polyps and matched normal mucosal specimens were
assayed for enzyme expression, while 37 paired samples were
assayed for adduct formation. CYP1A1 and 1A2 were undetected
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present. BaP induced CYP1A1/1A2 GST a and p to high levels in
mucosa but in polyps only CYP1A1/1A2 were induced to low
level. BaP:DNA adduct levels were 83.7 ± 15 polyps vs 128 ± 19
mucosa; P < 0.0001).
Intestinal polyps show reduced bioactivation enzyme expres-
sion and sustain less DNA damage from BaP, than normal mucosa.
Therapy to restrain bioactivation may inhibit carcinogenesis.
1.4 The coordinated modulation of the fibroblast
growth factor dual receptor mechanism during
transformation from human colon adenoma to
carcinoma
GC Jayson1, C Vives1, C Paraskeva2, K Schofield1,
J Coutts1, A Fleetwood1 and JT Gallagher1
1CRC Dept. Medical Oncology, Christie Hospital and Paterson Inst.,
Wilmslow Rd, Withington, Manchester M20 4BX, UK; 2CRC Dept. Colorectal
Biology, University of Bristol, Bristol, UK
Basic fibroblast growth factor (bFGF) is the prototypic member of
a family of cytokines that express a mandatory dependence on
heparan sulphate for their ability to activate the cell surface signal
transducing receptor. We have investigated this dual receptor
mechanism in a novel model of the transformation from human
colon adenoma to carcinoma, in vitro. RT-PCR studies showed that
mRNA for FGF receptors 1 and 2 were expressed in both the
adenoma and carcinoma cells, whereas immunocytochemistry
showed that the expression of the FGF R1 was significantly
reduced in the carcinoma cells. The molecular weight of the FGF
receptors was compatible with the 3-immunoglobulin loop form of
the FGF receptors, suggesting that heparan sulphate was required
for their activation by bFGF. We have reported that the composi-
tion and sequence of human colon adenoma and carcinoma
heparan sulphate (HS) differs in a defined and specific manner
(Jayson GC et al (1998) J Biol Chem 273: 51–57). The functional
significance of these changes was assessed by affinity co-electro-
phoresis which showed that the affinity of adenoma HS for bFGF
was tenfold greater than that of the carcinoma HS (Kd 220 nM vs
2493 nM, respectively). In addition, Northern blotting studies of
the expression of syndecan 1 and 4 mRNA showed that proteo-
glycan core protein expression was significantly reduced in the
carcinoma cells. This reduction in HS-bFGF affinity and proteo-
glycan mRNA was associated with a reduced biological response
to bFGF in the carcinoma cells that could be partially reversed by
the addition of exogenous heparin, suggesting that both the proteo-
glycan and signal transducing receptor control the cells’ response
to bFGF. The data show that the production of poorly functional
HS, lower amounts of proteoglycan and reduced FGF receptor
protein accompany transformation in this model. The implication
is that either the carcinoma cells are less dependent on exogenous
growth factor activity than the adenoma cells or that these alter-
ations contribute to the malignant phenotype. If these findings are
common to a range of malignancies the clinical implication is that
anti-growth factor strategies should be directed against either pre-
neoplastic lesions or normal cells, such as endothelial cells, that
have a greater growth factor requirement.
1.5 Insulin-like growth factor binding protein 3
(IGFBP-3) enhances p53-dependent apoptosis in
oesophageal cancer cells
AD Hollowood, T Lai, CM Perks, PV Newcomb,
D Alderson and JMP Holly
University Department of Surgery, Bristol Royal Infirmary, Bristol, BS2 8HW,
UK
The dysplasia to cancer sequence involves mechanisms in which
apoptosis fails to occur appropriately. The tumour suppressor gene
p53 is involved in this sequence in Barrett’s oesophagus, being a
transcriptional activator of target genes responsible for cell cycle
control and apoptosis. IGFBP-3 is one such target gene
(Buckbinder et al (1995) Nature 377: 646; Ludwig et al (1996)
Mol Cell Biol 16: 4952) with an important link to cancer. Recent
studies have shown a strong association between cancer risk and
high levels of IGF accompanied by low levels of the main IGF
carrier protein IGFBP-3 (Hankinson et al (1998) Lancet 351:
1393; Chan et al (1998) Science 56: 523). Conversely, apoptotic
rates are increased experimentally with low levels of IGF-I.
The aim of this investigation was to see if a direct link exists
between IGFBP-3, p53 and apoptosis in an oesophageal cancer
cell line shown to be devoid of IGF responsiveness.
KYSE 190 oesophageal carcinoma cells were grown in serum-
free media for 24 h prior to dosing with IGFBP-3. Cells were
subsequently exposed to UV irradiation. Levels of p53 within the
cell were detected by Western immunoblotting with a specific
monoclonal antibody. Cell death was measured by trypan blue
exclusion and apoptosis confirmed by measurement of a pre-G1
peak using flow cytometry.
Levels of p53 peaked within 2 h following exposure to UV irra-
diation and returned to basal levels after 24 h. Pre-incubation with
IGFBP-3 resulted in a 46% increase in the UV induced level of
p53 at 2 h with a further 42% increase at 8 h. UV irradiation
induced an 86% increase in cell death, with a further 85% increase
for cells preincubated with IGFBP-3 (P = 0.004).
IGFBP-3, independent of IGF-I, dramatically accentuates UV-
induced apoptosis with concomitant increases in p53 concentra-
tions. Delineating the mechanism of action of IGFBP-3 in such a
model could lead to a better understanding of the transition from
dysplasia to cancer.
1.6 p53 protein overexpression correlates with phenol
sulphotransferase (SULTIA1) genotype in colorectal
cancer
S Anwar2, AA Fryer2, RAHJ Gilissen1, T Holland2,
DE Bamber2, JB Elder2, J Elder2, J White2, EJ Bicknell2, 
RC Strange2 and MWH Coughtrie1
Departments of 1Molecular & Cellular Pathology, University of Dundee,
Ninewells Hospital & Medical School, Dundee DD1 9SY, UK; 2Centre for Cell
& Molecular Medicine, School of Postgraduate Medicine, Keele University,
North Staffordshire Hospital, Stoke-on-Trent ST4 7QB, UK
Sulphation is a phase II detoxifying reaction, catalysed by sulpho-
transferases (SULT). Like the other polymorphic, xenobiotic-
metabolizing enzymes, these enzymes catalyse the detoxification
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dates for cancer susceptibility. Mutations in the SULTIA1 gene,
which is the major form of phenol sulphotransferase, has been
associated with defective enzyme activity and protein stability.
p53 protein over-expression is regarded as a marker for mutations
in p53 gene. Accordingly, we examined the p53 over expression in
a cohort of patients with mutations in SULT1 AI genotype.
Sixty-eight patients were SULTIA1 genotyped using a PCR
assay developed in our laboratory. Wild-type SULTIA1*1 alleles
were differentiated from mutant SULTIA1*2 alleles using diges-
tion with HaeII. These patients were analysed for p53 protein
over-expression using immunohistocytochemistry on resected
colorectal tumour samples. Positivity was graded from 0–3.
Our data showed that there was a gene dosage effect
for p53 positivity in patients with SULTIA1*2 alleles. Thus, the
propor-tion of patients who were p53-positive was 50% in
SULTIA1*1/SULTIA1*1 homozygotes, 64% in SULTIA1*1/-
SULTIA1*2 heterozygotes and 100% in patients with
SULTIA1*2/SULTIA1*2 homozygous mutant genotypes (trend
test:  P = 0.04).
This data showing, in colorectal tumours, an association
between SULTIA1 mutant alleles and over-expression of p53
protein in combination with data showing associations between
outcome and expression of p53 suggest that polymorphism at this
locus may be a factor determining outcome. Further work is
required to elucidate the mechanism of this effect.
1.7 Detection of p53 point mutations in circulating
tumour cells in patients with colorectal cancer
SK Jonas, A Tarragona, KA Feldmann, RQ Wharton,
K Stupnicka and TG Allen-Mersh
Department of Gastrointestinal Surgery, Imperial College School of Medicine,
Chelsea & Westminster Hospital, 369 Fulham Rd. SW10 9NH, UK
The clinical relevance of identifying disseminated cells from solid
tumours in the circulation using RT-PCR and epithelial specific
markers has still to be established. Only a very small proportion of
these cells will successfully achieve metastasis. To examine the
extent to which a subpopulation of these identified cells harbour
p53 mutations, we have isolated tumour cells from the circulation
of colorectal cancer patients and studied them for their p53 muta-
tional profile.
p53 mutations between exons 4 and 9 were studied in tumour
cells isolated from the circulation as well as in matched tumours
from 12 colorectal cancer patients. Multiple venous blood samples
(three per patient) were collected via a cannula and specifically
selected for epithelial cells using immunomagnetic beads labelled
with a monoclonal anti-human Ber-EP4 antibody. Total RNA was
extracted on these isolated cells followed by two-step RT-PCR for
both blood and tissue. All PCR products were initially screened for
SSCP by automated gene scanning using a 310 ABI PRISM gene
scanner which is based on rapid mutation detection. Products that
resulted in mobility shifts were confirmed by automated
sequencing.
In five of 12 patients, a total of 13 mutations were detected in
the circulation. In three of these patients mutations were detected
in known hotspots (codon 248, 273). In a further three patients a
total of three mutations were detected. Some of these mutations
identified have not previously been reported in colorectal cancer
and mutations in blood and matched tissue did not correspond in
any patient. No mutations were detected in the blood or tissue
from six normal ‘no-cancer’ control patients. Multiple blood
sampling increased the frequency of detecting different p53 muta-
tions in circulating tumour cells, suggesting that these cells circu-
late in clusters constituting distinct cell populations. These clusters
may have a selective advantage in achieving metastasis compared
with the majority of cells derived from the primary tumour. The
difference in mutational pattern between blood and matched tissue
from the same patient may be due to sample variation resulting in
undetected mutations from different areas of the tumour.
These results demonstrate for the first time that, with the use of
immunomagnetic beads for epithelial cell selection, mutations in
the p53 gene can be detected in circulating tumour cells. The
advantage of convenience in obtaining peripheral blood samples,
the greater potential for identifying multiple mutations among
cells within the circulation, and difficulties with solid tumour
sampling error make circulating tumour cells attractive sources of
information about the accumulation of additional mutations during
the development of metastasis.
1.8 The effect of glutathione S-transferase GSTT1 and
GSTM1 genotypes on susceptibility and outcome in
colorectal cancer
J White, S Anwar, M Deakin, A Fryer, J Elder, D Bamber, 
P Jones, R Strange
Centre for Cell and Molecular Medicine, School of Postgraduate Medicine,
N. Staffordshire Hospital, Stroke on Trent, Staffs, UK.
The genes encoding for the glutathione S-transferase GSTT1 and
GSTM1 proteins are polymorphic with common null alleles
(Chevenix-Trench et al, 1995; Deakin et al, 1996; Howells et al,
1998). These enzymes are important mediators of in-vivo detoxifi-
cation since they catalyse the conjugation of glutathione to a wide
variety of environmental carcinogens. Consequently, failure to
express these enzymes may be associated with impaired
carcinogen detoxification and an increased risk of colorectal
cancer (Deakin et al, 1996; Cheverix-Trench et al, 1995). Further,
recent evidence suggests that these polymorphisms also influence
outcome in several common cancers. Accordingly, we have
examined the influence of GSTT1 and GSTM1 genotypes on
susceptibility and outcome in colorectal cancer.
Blood samples were obtained from cases (n = 248) and controls
(n = 510) and genomic DNA isolated from lymphocytes by
phenol/chloroform extraction. Using PCR (Chevenix-Trench et al,
1995; Howells et al, 1998), the null and expressing genotypes for
both GSTT1 and GSTM1 were identified in both study and control
populations. Clinical data, including follow-up data, was also
obtained for the case group.
In the case group, the frequency of GSTT1 null was signifi-
cantly increased compared to controls (P = 0.0036). GSTM1 geno-
type was not significantly associated with susceptibility or
outcome. Analysis of those individuals who underwent ‘curative’
surgery (n = 144) showed a median time to recurrence of 3.49
years in those patients who were both GSTT1null/GSTM1null
compared to > 10 years for those patients who were non
GSTT1null/GSTM1null (P = 0.037).
We have confirmed that GSTT1 null is associated with suscepti-
bility to colorectal cancer. We have also shown that patients with
both GSTT1 null/GSTM1 null genotypes are at increased risk of
recurrence. This data supports our results in ovarian cancer
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1.9 Polymorphisms in the p53 family of tumour
suppressor genes and suceptibility to breast cancer
KL Søndergaard1, D Wheatley2, S Kelly2 and AG Demaine1
1Department of Molecular Medicine, Plymouth Postgraduate Medical School,
Plymouth PL4 8AA, UK; 2Oncology Dept., Derriford Hospital, Plymouth
PL6 8DH, UK
p73, a novel homologue of the p53 tumour suppressor gene family,
has recently been identified and mapped to chromosome 1p36, a
region frequently deleted in several cancers. p73 has been demon-
strated to be monoallelically expressed. An allelic polymorphism
exists within its 5¢ untranslated region consisting of a double
nucleotide substitution (G®A) and (C®T) at position 4 and 14 of
exon 2. We investigated the frequency of this genotype in the DNA
extracted from peripheral blood samples of 75 patients with breast
cancer and 100 sequential cord blood samples using PCR-RL. Out
of the 75 patients, 28 (37.3%) were heterozygous for the C/T poly-
morphism and out of 100 controls, 33 (33%) also had the C/T
polymorphism. The frequency of the C/T polymorphism was
compared with tumour grade, size and node involvement and no
significant correlation was found between clinical features and
genotype. However, a non-significant trend was observed with the
age of diagnosis. Twice as many patients diagnosed after 40 years
of age had the GC monoallelic genotype (65.6%, 40 of 61) rather
than the C/T polymorphism (34.4%, 21 of 61). Patients diagnosed
before 40 years of age had a similar frequency of p73 genotypes.
As half of all breast tumours harbour alterations in the p53 tumour
suppressor gene, we also investigated the frequency of p53Pro/Arg
polymorphisms in all of the samples. Interestingly, 53.2% (25 of
47) of the G/C p73 genotype was p53Pro/Arg heterozygous and
44.7% (21 of 47) was p53 Arg homozygous. In contrast, 39.3% (11
of 28) of the C/T p73 genotype was p53 Pro/Arg heterozygous and
60% (17 of 28) was p53Arg homozygous. It has recently been
shown that individuals homozygous for p53Arg are 7 times more
likely to develop human papillomavirus (HPV) associated cancer.
An association may exist between p73 and p53Pro/Arg genotype
in patients with breast cancer.
1.10 CDKN2A germline mutations in UK patients with
multiple primary melanomas and familial melanoma
RM MacKie, N Andrew, WG Lanyon and JM Connor
Department of Dermatology and Medical Genetics, Glasgow University,
Glasgow, UK
Approximately 5% of all melanoma patients have a family history
of melanoma. We have investigated 16 families in the North of
the UK and found that 6 of these have functionally damaging
mutations of the CDKN2A (p. 16) gene. There are four different
mutations observed. One family has an Arg 24 Pro substitution,
one a stop codon at codon 44 of exon 1 and 4 have Met 53 Ile
substitutions. The remaining ten members of multiple melanoma
families do not appear to have CDKN2A mutations.
We have further investigated 17 patients with multiple primary
melanomas and a negative family history after exhaustive ques-
tioning and examination. Two of these 17 also have CDKN2A
mutations, one a Met 53 Ile substitution in exon 2 and one a G-T
substitution at IVS2 + 1 splice donor site.
This is the first report from Europe of CDKN2A mutations in
patients with multiple primary melanomas. There is one other
report in the literature from Canada of patients with multiple
primary melanomas and a negative family history having
CDKN2A mutations.
Our observations to date suggest that CDKN2A germline muta-
tions may be commoner than previously recognized. However it is
also clear that two thirds of familial melanoma patients and a
proportion of those with multiple primary melanomas may have
mutations elsewhere. The search for other mutations continues.
2.1 Cytotoxicity of the non-steroidal anti-inflammatory
drugs in human colonic cancer cells: a role for the
polyamines?
PB Low and HM Wallace
Departments of Medicine & Therapeutics and Biomedical Sciences,
University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
Epidemiological studies have shown that regular use of non-
steroidal anti-inflammatory drugs (NSAIDs) can decrease the inci-
dence of colorectal cancer in man by as much as 50% (Rosenberg
et al (1991) J Natl Cancer Inst 83: 335). The mechanism is,
however, unclear. It has been suggested that the chemopreventa-
tive effect is mediated through the prostaglandins with NSAIDs
decreasing their production via inhibition of COX enzymes.
Recently this theory has been questioned since, in cell culture,
addition of prostaglandins did not reverse the effects of the
NSAIDs on cell proliferation (Hanif et al (1996) Biochem
Pharmacol 52: 237). Another possibility is that NSAIDs interfere
with polyamine metabolism which consequently affects cell
growth. The polyamines, like the prostaglandins, are essential for
growth, are found in high concentrations in many cancers (Wallace
(1995)  Proc Nutr Soc 55: 351) and can regulate apoptosis in
human cells (Lindsay and Wallace (1997) Br J Pharmacol Suppl. 
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on cell growth and polyamine metabolism in a human colorectal
cancer cell line (HT115). Salicylate, sulindac and naproxen all
inhibited the growth of the cells with IC50 values of approximately
7.5 mM, 0.75 mM and 3 mM respectively. Cytotoxicity was
observed at higher doses. Polyamine content was decreased in
cells treated with NSAIDs. Addition of exogenous spermidine
resulted in the recovery of both cell growth and polyamine
content. Therefore we suggest that the loss of polyamines induced
by NSAIDs contributes significantly to the observed cytotoxicity
and therefore the chemopreventative effects of these drugs.
2.2 Sulindac, TNFa signalling and apoptosis in
intestinal epithelium
B Ansari, A Kubba, K Atherton and FC Campbell
Department of Surgery, University of Newcastle, Newcastle, UK
Sulindac sulphide may promote apoptosis and inhibit carcinogen-
esis through COX-2 independent mechanisms but relevant molec-
ular pathways are unclear. TNF-a is an inflammatory cytokine
which influences apoptosis through activation of NF kappa B (NF-
kB). NF-kB induces transcription of an anti-apoptotic gene, IEX-
1L. We test the hypothesis that sulindac sulphide promotes
apoptosis in intestinal epithelium partly through inhibition TNFa-
induced NF-kB activation.
The HCT116 colonic carcinoma and INT 407 benign human
embryonic intestinal cell lines were transiently transfected with a
NF-kB luciferase reporter construct, incorporating 3 synthetic
copies of the NF-kB promotor upstream of transcription start site
(3 enh-kb-CONA-luc) or control empty vector lacking kappa B
sequences (CONA-luc). Cells were pre-incubated with or without
sulindac sulphide (50–150 mM) then stimulated with 10 ng ml–1
recombinant human TNFa. Apoptosis was assessed by acridine
orange staining.
TNFa-stimulated NF-kB activation in transfected HCT116 and
INT 407 cells, by up to fourfold. Sulindac sulphide induced dose
dependent apoptosis in both cell lines, of up to 90% at 125 mM.
Sulindac sulphide inhibited TNFa-stimulated NF-kB activation in
both cell lines.
Sulindac sulphide may retard carcinogenesis in intestinal
epithelium, partly by inhibition of TNFa induced NF-kB activa-
tion and consequent promotion of apoptosis.
2.3 Effect of soy or rye on colon tumours in AOM-
treated rats
MJ Davies1, EA Bowey1, H Adlercreutz3, IR Rowland1 and
PC Rumsby1
1BIBRA International, Carshalton, Surrey SM5 4DS, UK; 2University of
Helsinki, Meilahti Hospital, Helsinki, Finland
The value of a diet high in plant material in the prevention of
cancer is apparent from epidemiological studies. Much current
interest has focused on the possible role of a group of plant
phenolic compounds with oestrogenic-like activity (phyto-oestro-
gens). In this study we have investigated the effects of isoflavones
derived from soy and lignans from rye bran on the development
colon tumours in F-344 rats treated with the carcinogen,
azoxymethane.
Male F-344 rats were fed a carefully-balanced high fat diet
based on isoflavone-free soy protein or the same diet with
isoflavones (IF) or rye bran (RB). After 2 weeks on the diet, the
rats received two injections of azoxymethane (AOM, 15 mg kg–1)
given 1 week apart. Animals were humanely killed after 12 or 31
weeks on the diet and the colons examined for aberrant crypt foci
(ACE), the number of crypts per focus and the presence of
tumours.
Analysis of the total number of ACF at 12 weeks revealed
no differences between any of the diets. The number of small ACF
(< 4 crypts/focus) was increased in the IF-containing group while
the RB group showed a decrease in the number of larger ACF
(> 6 crypts/focus). There were no differences in the small numbers
of ACF which remained at 31 weeks. However, the number of
tumours found in the colon at 31 weeks was significantly
decreased in the RB group (mean tumour/rat: control 1.36,
RB 0.166) while the IF group showed no change (mean
tumour/rat, 1.38).
In conclusion, the supplementation of rye bran containing
lignans was highly protective against AOM-induced tumours in
the rat colon and this may involve the retardation of progression of
early aberrant crypts although the mechanism of action requires
further study. Soy isoflavones do not appear to offer any protection
against AOM-induced colon cancer in this model.
This study was funded by EU FAIR Programme (Contract
number 95/0894) and the World Cancer Research Fund.
2.4 Inhibition of leukaemia growth and apoptosis
induced by phenethyl isothiocyanate and cysteine
conjugate
K Xu and PJ Thornalley
Department of Biological Science, Essex University, Colchester CO4 3SQ,
UK
Phenethyl isothiocyanate (PEITC) and its cysteine conjugate
(PETC-Cys) have cancer chemopreventive activity in vivo. PEITC
and PETC-Cys inhibited the growth of human leukaemia 60
(HL60) cells in serum-free medium in vitro – the GC50 values were
0.84 ± 0.01 mM and 0.96 ± 0.02 mM respectively. The anti-prolifer-
ative activity of both compounds decreased with addition of
increasing percentage of serum in the culture medium but the
effect was more marked for PETC-Cys than for PEITC: with 25%
serum, the GC50 values were 4.57 ± 0.21 mM and 8.05 ± 0.20 mM
respectively. Both compounds had much weaker effects on
concanavalin A-stimulated proliferating peripheral human
lymphocytes: the TC50 values were 53.1 ± 4.3 and 90.8 ± 2.7 mM
respectively. The inhibition of HL60 cell growth was characterized
by a rapid interaction of PEITC with the cells in the first hour of
culture – or exposure to the PEITC liberated from the cysteine
conjugate PETC-Cys in the initial 3 h of culture. This interaction
induced commitment to apoptosis which developed in the initial
24 h. Induction of apoptosis was judged by flow cytometry of cells
stained with propidium iodide and by fragment ladders in Agarose
gel electrophoresis of cellular DNA. Inhibition of macromolecular
synthesis was also an early feature of the commitment to cell
death. There was an increase of caspase-3 activity – determined by
fluorimetric measurement of hydrolysis of the synthetic caspase-3
substrate  N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin
but this was probably a marker rather than an obligatory mediating
factor of isothiocyanate-induced apoptosis since the specific
caspase-3 inhibitor N-acetyl-Asp-Glu-Val-Asp-aldehyde had no
effect. The involvement of other caspases in isothiocyanate-
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tosis with the non-selective caspase inhibitor N-benzyloxycar-
bonyl-Val-Ala-Asp(OMe)-fluoromethylketone. These effects may
contribute to inhibition of pre-clinical tumour growth in chemo-
preventive activity.
2.5The chemopreventive agent curcumin suppresses
cyclooxygenase-2 expression in colon cells by
inhibiting the NIK/IkB kinase activation of NF-kB
SM Plummer1, KA Holloway2, RJL Munks1, MM Manson1,
A Kaptein3, S Farrow3 and A Hubbard2
1MRC Toxicology Unit, 2Centre for Mechanisms of Human Toxicity, University
of Leicester, Leicester LE1 9HN, UK; 3Glaxo Wellcome Research and
Development, Stevenage, Hertfordshire SG1 2NY, UK
Curcumin, a chemical component of the curry spice turmeric,
prevents colon cancer in animal models of this disease. We have
previously shown that curcumin inhibits TNFa- and fecapentane-
12-mediated induction of COX2 mRNA, NF-kB-DNA binding, in
a normal colon epithelial cell line (HCEC) and NF-kB dependent
transactivation in SW480 colon carcinoma cells (Holloway KA et
al (1998) Br J Cancer78: 157). Since NF-kB is important in the
regulation of the COX2 gene by inflammatory cytokines these data
indicate that curcumin may inhibit COX2 induction in part via
inhibition of NF-kB. Activation of NF-kB is modulated by a
kinase signalling complex which contains NF-kB inducing kinase
(NIK) and the IkB kinases (IKK) aand b. Phosphorylation of IkB
by IKKa/btargets the protein for degradation via the proteosome
which releases NF-kB into the nucleus to activate transcription. To
determine whether curcumin would inhibit the degradation of the
NF-kB sequestering protein IkB, we performed Western blot
analysis with IkB-specific antibodies. Curcumin completely
blocked the degradation of IkB caused by TNFa(10ng ml–1) in
HCEC cells. To test the possibility that curcumin acts through inhi-
bition of the NIK/IKK complex, we measured its ability to inhibit
NF-kB-mediated alkaline phosphatase reporter gene activity (in
the p4NFkB construct), induced either by exposure to TNFa(10
ng ml–1) or by overexpression of the NIK kinase, following trans-
fection of a NIK expression construct (pcDNA3-NIK). These
experiments were carried out in a model cell system HEK293,
circumventing problems associated with extremely poor transfec-
tion efficiency in HCEC cells. Curcumin (20mM) inhibited TNFa-
mediated induction of p4NFkB alkaline phosphatase activity by 54
±12% (s.d.) and a similar inhibition (49 ±5%) was observed
following induction of reporter gene activity by overexpression of
NIK, suggesting curcumin acts via inhibition of the NIK kinase
and/or signalling kinases downstream of NIK, namely IKKa
and/or b.
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2.6Does rice contain cancer chemopreventive agents?
A Dinh1, T Kokubun2, A Hudson1, M Simmonds2 and 
A Gescher1
1MRC Toxicology Unit, University of Leicester, Leicester LE1 9HN, UK;
2Jodrell Laboratory, Royal Botanic Gardens, Kew, Richmond, Surrey
TW9 3AB, UK
There is growing public awareness of the potential beneficial
effects on health of diet constituents. Whilst certain foods, such as
soya beans and cruciferous vegetables, are thought to contain
cancer chemopreventive agents, relatively little is known whether
staple components of the human diet, such as rice (Oryza sativa,
Gramineae), contain chemopreventive substances. We have inves-
tigated the growth-inhibitory properties (anticlonogenic activity)
in SW 480 human colon cancer cells of extracts of cooked rice.
Two commercially available rice varieties were studied, a highly
refined (polished) white variety (var. japonica) and a brown
variety (var. javanica). Rice grains (1.5kg) were cooked in water
and homogenized to a slightly viscous paste, which was extracted
successively with diethyl ether, ethyl acetate and aqueous
methanol (MeOH, 60%). Residues of extracts after filtration and
concentration were analysed by HPLC (C18 column, mobile phase:
aqueous MeOH 40% to 100%, acetic acid 2%; UV detection
260nm). Ethyl acetate extracts of the brown variety (‘javEtac’)
contained polyphenols and flavonoids, whilst such compounds
could not be detected in extracts of the refined variety. ‘javEtac’
was fractionated (Amberlite XAD-2) into 10 fractions. Three of
these fractions, when tested at 50mg ml–1, decreased the clono-
genicity of the cells by more than 50% of controls. The active
fractions were further fractionated by semi-preparative HPLC.
Constituents of these subfractions were tentatively identified by
co-chromatography as ferulic acid, p-methoxycinnamic acid
(MCA) and several flavonoids. When tested separately, ferulic
acid and MCA at 0.2mMfailed to affect cell clonogenicity,
whereas the phenol gallic acid displayed an IC50 value of 7mM.
The results suggest that the bran of brown varieties of rice may
contain growth inhibitory agents of low molecular weight, the
nature of which needs identification.
Supported by the World Cancer Research Fund.
2.7Mechanisms of action of the dietary
chemopreventive agent genistein
EA Hudson, L Howells, P Chapman and MM Manson
MRC Toxicology Unit, Hodgkin Building, Leicester University, Leicester
LE1 9HN, UK
Epidemiological evidence has shown a potentially chemoprotec-
tive effect of Asian diets, which are high in soy products, when
compared to Western diets. The isoflavanoid genistein, identified
as an active component of soy, has been shown to exert anti-
tumour activity in a range of rodent models. Several possible
mechanisms of action have been proposed, including inhibition of
tyrosine kinase, modulation of oestrogen receptor (ER) signalling,
and inhibition of ornithine decarboxylase (ODC) activity.
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ornithine decarboxylase activity of a panel of human breast (HBL
100 ER+ve immortalized, MCF7 ER+ve tumour and MDA468
ER–ve tumour) and colon (HCEC immortalized, HT29 and
SW480 tumour) cell lines. Growth curves were performed for each
of the cell lines treated with genistein at 0, 10, 25, 40, 50 and
75 mM for 10 days. ODC activity in crude cell extracts was deter-
mined by measurement of 14CO2 released from labelled substrate.
Genistein inhibited the growth of all six lines in a time and dose-
dependent manner, the breast cells being more sensitive than the
colon lines. The effect of genistein treatment on ODC activity
varied with cell type. After 5-h treatment, ODC activity appeared
to be increased in a dose-dependent manner in the HBL100 and
SW480 cell lines (´3 and ´2 fold respectively at 75 mM), but
decreased in the MDA468 cells (40% control values at 40 mM).
ODC activity was not altered in the other cell lines, and at this time
point, modulation of ODC activity did not correlate with the effect
of genistein on cell growth. Preliminary results obtained with the
SW480, MCF7, HBL100 and MDA468 lines after 24-h treatment
showed a dose-dependent decrease in activity, suggesting that the
effect of genistein on ODC activity is time-dependent, and may
correlate more closely with the effect on growth at later time
points.
The significance of the initial increase in ODC activity in the
HBL 100 and SW 480 cells, and the relationship between inhibi-
tion of ODC activity and cell growth is currently under further
investigation.
2.8 Evidence for autoproteolysis of substrate-
inactivated O6-methylguanine-DNA methyltransferase
following DNA repair
GN Major1,2, GB Notarianni1, SJ Ross1,3, MC Case1,2,4,
JA Brannigan5, DI Roper5, PM Potter 6, TP Brent6 and 
PCE Moody7
1Medical Molecular Biology Group (Department of Medicine), 2Centre for
Liver Research, and Departments of 3Biochemistry and Genetics, and
4Pathology, Medical School, University of Newcastle upon Tyne, NE2 4HH,
UK; 5Protein Structure Research Laboratory, Department of Chemistry,
University of York, YO1 5DD, UK; 6Department of Molecular Pharmacology,
St. Jude Children’s Research Hospital, Memphis, TN 38105–2794, USA;
7Department of Biochemistry, University of Leicester LE1 7RH, UK
The anti-carcinogenic DNA repair and drug resistance enzyme,
O6-methylguanine-DNA methyltransferase (MGMT), unusually
functions in a single catalytic cycle. MGMT removes the methyl
group from the O6 atom of guanine, thereby restoring native
guanine in DNA, and transfers the methyl group to itself at a
specific cysteine residue. This automethylation inactivates the
enzyme, which is not regenerated. That cells do not appear to
demethylate and, hence, recycle alkylated MGMT as the active
enzyme may be explained by others and our past findings of rapid
degradation of the alkylated enzyme via the ubiquitin pathway.
The present study arose from a potentially related observation,
namely, our identification of a eukaryote thiol protease (active site
histidine) motif in human MGMT (Collier et al (1996) J Hepatol
25: 158–165). The presence of this motif raises the possibilities of
MGMT having an intrinsic protease function and autoprotease
activity that may be involved in enzyme degradation.
Here, we found that apparently homogeneous preparations (by
several criteria, including their attaining theoretical maximum
specific activity of ~ 46 nmol mg–1 protein, and yielding clean
N-terminal amino acid sequence) of recombinant human MGMT
were able to undergo a time- and concentration-dependent degra-
dation following repair of O6-methylguanine-DNA, that may be
autoproteolytic in mechanism. This was observed for rMGMT
prepared in two different ways: from a maltose binding protein
(MBP)-MGMT fusion protein, following specific proteolytic
cleavage of MBP from MGMT, and from unmodified human
MGMT, over-expressed in E. coli. Putative methylated MGMT
autoprotease activity was prevented by the thiol protease-specific
inhibitor E64, and in an inhibitor concentration-dependent manner.
The mixed-specificity thiol/serine protease inhibitor, leupeptin,
similarly inhibited methylated MGMT degradation. Methylated
MGMT autoproteolysis was also inhibited in the presence of
excess native MGMT, indicating that (i) non-methylated enzyme
is without autoprotease activity, (ii) protease activity appears upon
DNA repair, (iii) the active enzyme is a potential substrate for
proteolysis, and (iv) any contaminating protease with the ability to
degrade MGMT would have to be highly specific, requiring acti-
vation by repair substrate O6-methylguanine-DNA. Highly puri-
fied MBP-MGMT was found to have DNA repair activity, but did
not undergo degradation following automethylation, suggesting
that MBP at the N-terminus of MGMT may have prevented
enzyme autoproteolysis. It also provides further evidence that
autoproteolysis seen with methylated rMGMT did not occur as a
result of contaminating protease action.
Overall, we interpret these findings to be compelling evidence
for MGMT having a catalytic site for proteolysis, and for it being
able to undergo autoproteolytic modification following DNA
repair.
2.9 Mouse models of DNA repair deficiencies
D Barnes1, A Klungland2, H Nilsen3 and T Lindahl1
1ICRF, Clare Hall Laboratories, South Mimms, Herts EN6 3LD, UK; 2The
National Hospital, Oslo, Norway, 3University for Science & Technology,
Trondheim, Norway
DNA repair systems in human cells are targeted against three main
types of lesions: (i) endogenous DNA damage generated by intra-
cellular hydrolysis, active oxygen, and reactive cellular metabo-
lites; (ii) mismatched nucleotides introduced by errors in DNA
replication; (iii) pyrimidine lesions resulting from cellular expo-
sure to ultraviolet light. Most DNA damage in normal proliferating
cells is due to endogenous attack, and this unavoidable but poten-
tially mutagenic and carcinogenic DNA damage is removed by
highly effective repair mechanisms. The most important of these is
base excision-repair. Two alternative strategies serve to correct an
altered base; in the major pathway DNA polymerase beta replaces
a single nucleotide, while a minor pathway involves replacement
of several nucleotides in a FEN1- and PCNA-dependent reaction.
We have reconstituted both branches of base excision-repair with
purified proteins and synthetic DNA substrates (Kubota et al
(1996)  EMBO J 15: 6662; Klungland and Lindahl (1997) EMBO J
16: 3341).
Two major forms of endogenous DNA damage are (i) hydrolytic
deamination of cytosine to uracil and (ii) oxidation of guanine
to 8-hydroxyguanine (8-oxoG); both are mutagenic lesions,
promoting GC to AT transitions and GC to TA transversions
respectively. Uracil in DNA is removed by uracil-DNA glycosyl-
ase (UDG); bacterial and yeast mutants are viable but exhibit an
increased spontaneous mutation frequency. Our group and others
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able to remove 8-oxoG opposite C (OGG1) and the cognate gene
has been mapped to 3p25, a locus often deleted in lung tumours
(Roldan-Arjona et al (1997) Proc Natl Acad Sci USA 94: 8016).
We have generated viable mouse models deficient in either UDG
or OGG1. Analysis of the mouse phenotypes with respect to spon-
taneous mutation frequency and tumour incidence will help to
evaluate the contribution of the UDG and OGG1 enzymes to the
maintenance of genetic stability, and the prevention of carcino-
genesis.
We have also generated a knockout mouse model for DNA
ligase IV, which is involved in DNA double-strand break repair
and V(D)J recombination; DNA ligase IV null mutation results in
embryonic lethality and the effects of the enzyme deficiency have
been further investigated in mouse embryonic fibroblast cell lines.
2.10 Tumour targeting of anticancer drugs and
oligonucleotides using polymeric carriers
R Duncan, YN Sat, R Satchi, E Gianasi, N Malik and 
S Richardson
Centre for Polymer Therapeutics, School of Pharmacy, 29–39 Brunswick
Square, London WC1N 1AX, UK
N-(2-Hydroxypropyl) methacrylamide (HPMA) copolymer-
doxorubicin (PK1) (Vasey P et al, (1998) Clin Cancer Res, (in
press)), HPMA copolymer-platinate (AP5070) (Gianasi E et al.
(1998) Br J Cancer 78: 156) and dendrimer-platinates (Malik N
and Duncan R (1997) Proc Intl Symp Control Rel Bioact Mater 24:
527) all show ability to localize selectively in solid tumour tissue
giving rise to significantly higher (> 70-fold) drug levels than can
be achieved by administration of free drug. This passive targeting
has been termed enhanced permeability and retention (EPR) effect
Matsumura Y and Maeda H (1986) Cancer Res 46: 6387) and it
can also be used to target combination therapy, e.g. PDEPT (Satchi
R and Duncan R (1998) Br J Cancer 78: 149) and used for delivery
non-viral vectors for DNA delivery.
Using s.c. B16F10 murine melanoma as a standardized
screening system we have compared the whole body pharmaco-
kinetics of the above mentioned conjugates and also poly-
amidoamines (PAAs) developed as endosomolytic polymers to
facilitate intracytoplasmic access of oligonucleotide delivery
systems. PK1 displayed tumour uptake in the range 1–14 % dose
g–1 with maximum uptake within 1 h. Due to plasma protein inter-
action the HPMA copolymer platinate had a longer circulation
time and as a result showed progressive tumour accumulation over
24–48 h, maximum uptake was in the range 8–13 % dose g–1. The
hyperbranched dendrimer-platinate behaved more like PK1 with
maximum tumour uptake at earlier time points, but the extent of
capture was less (0.5–4% g–1) and rate of egress from the tumour
was faster. PAAs accumulated progressively in B16F10 after i.v.
administration over 5 h. After administration of PK1 there is a lag
phase (30–60 min) before free doxorubicin appears. This is consis-
tent with intracellular drug release following pinocytic uptake of
the conjugate. Administration of HPMA copolymer-cathepsin B
5 h after administration of PK1 (as a model to study the PDEPT
concept) led to immediate release of doxorubicin indicating the
possibility to modulate drug release extracellularly. This library of
information regarding a variety of polymeric vectors sheds light on
the factors important for tailor-making improved polymeric drugs
and DNA vectors.
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P1 The generation of antibody fragments to the DNA
adduct 8-oxoguanine
CH Seedhouse1, JH Hendry2, GP Margison2 and 
MJ Embleton1
CRC Sections of 1Cell and Tumour Biology and 2Genome Damage and
Repair, Paterson Institute for Cancer Research, Christie Hospital NHS Trust,
Wilmslow Road, Manchester M20 9BX, UK
Oxidative damage to cellular DNA has been implicated in various
age-related degenerative diseases, including cancer and heart
disease. We describe a novel approach based on the use of phage
display libraries to generate recombinant human antibody
fragments against the DNA adduct 8-oxoguanine, which is an
abundant mutagenic base product of oxidative damage. Several
monoclonal single chain Fv (scFv) antibodies have been gener-
ated, and characterization in a quantitative ELISA system has
shown one of these antibodies to have a lower limit of detection of
2.5 ´ 10–13 mol 8-oxoguanine in a synthetic oligonucleotide. The
antibody also binds to 8-oxoguanine lesions introduced into
plasmid DNA by treatment with methylene blue and white light.
The extent of antibody binding to treated DNA was proportional
to the concentration of methylene blue and therefore to the level of
8-oxoguanine. The antibody also inhibits the release of 8-oxogua-
nine from 8-oxoguanine-containing oligonucleotides by the E. coli
formamidopyrimidine-DNA glycosylase as determined using an
in vitro system. Further experiments are in progress to exploit the
ability of the antibody fragment to detect the adduct, and its
biological activity in relation to DNA repair.
This work is supported by the Cancer Research Campaign.
P2 N-desmethyltamoxifen forms DNA adducts in
treated rats
K Brown, R Heydon, R Jukes, INH White and EA Martin
MRC Toxicology Unit, University of Leicester, Leicester LE1 9HN, UK
The anti-oestrogen tamoxifen is currently undergoing evaluation
as a chemopreventive agent in women at an increased risk of
developing breast cancer. However, tamoxifen treatment is associ-
ated with an increased incidence of endometrial cancer, and
administration to rats causes hepatic tumours. Tamoxifen requires
metabolic activation to electrophilic species before it can react
with DNA, forming adducts detectable using the 32P-post-labelling
assay. Using HPLC with on-line radiochemical detection 32P-post-
labelled tamoxifen DNA adducts can be separated into at least
12 individual peaks (Martin EA et al (1998) Carcinogenesis 19:
1061–1069). The major metabolites of tamoxifen in both rat and
human liver are N-desmethyltamoxifen and 4-hydroxytamoxifen.
However, the two major DNA adducts detected in the livers of
tamoxifen-dosed rats arise as a consequence of a-hydroxylation,
which is a minor metabolic pathway. These adducts contain
tamoxifen linked via the a-carbon to the exocyclic amino group of
deoxyguanosine. The relative importance of each adduct in the
carcinogenic process is currently unknown and it is possible
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4-hydroxytamoxifen may be important.
In order to identify which of the in vivo adducts contain an
N-demethylated tamoxifen moiety, rats were dosed with
N-desmethyltamoxifen (40 mg kg–1 i.p. daily) for 4 days. This
metabolite was synthesized from tamoxifen by a novel route
involving formation of a demethylated trichloroethyl carbamate
derivative followed by reduction with zinc in acetic acid. The liver
DNA was extracted and subjected to 32P-post-labelling and HPLC
separation. Two peaks were observed. The largest peak co-eluted
with one of the major rat liver adducts described above. The
second peak co-eluted with a minor, more polar tamoxifen adduct.
LC-MS analysis of the liver extracts showed the absence of
tamoxifen, confirming that the adducts were derived from N-des-
methyltamoxifen. The levels of adducts formed, 100 ± 33 10–8
nucleotides, n = 4, was comparable to that seen when rats were
dosed with tamoxifen itself (109 ± 36 adducts 10–8 nucleotides,
n = 3). The finding that the main N-desmethyltamoxifen adduct
co-elutes with one of the major tamoxifen adducts demonstrates
that loss of a methyl group does not significantly affect chromato-
graphic mobility in this HPLC system. This highlights the need to
identify all the components of the main adduct peaks since it is
likely that additional structurally different adducts may also elute
at this time.
P3 Modification of nucleotides and 2¢-deoxyguanosine
by nitrosated indoles results in deamination,
depurination and the formation of a novel product
oxanine via a transnitrosation mechanism
LT Lucas1, D Gatehouse2 and DEG Shuker1
1Biomonitoring Section, MRC Toxicology Unit, University of Leicester,
Leicester, LE1 9HN, UK; 2Genetic and Reproductive Toxicology, Glaxo
Wellcome Research and Development, Ware, Herts, SG12 0DP, UK
Indoles are a major group of naturally occurring compounds with
chemoprotective properties found in cruciferous vegetables.
Synthetic 3-substituted indoles have shown potential as pharma-
ceutical agents (Sinha and Jain, 1994) Indoles can be readily
nitrosated to give the corresponding N-nitrosoindoles and this
pathway is of concern since there are endogenous sources of nitrite
and nitrosating agents. Indole-3-acetonitrile, a precursor in
Chinese cabbage, becomes mutagenic upon nitrite treatment
(Wakabayashi et al, 1985) and has been shown to form DNA
adducts in rat stomach (Yamashita et al, 1988). In this study, the
reaction of a series of nitrosated indoles with 2¢-deoxyguanosine-
5¢-monophosphate (dpG), 2¢-deoxyadenosine-5¢-monophophate
(dpA) and 2¢-deoxyguanosine (dGuo) was investigated. Indole-3-
acetonitrile, indole-3-acetamide and indole-3-acetic acid methyl
ester were all nitrosated and the products characterized by mass
spectrometry, NMR and elemental analysis. Incubations between
the nitrosated indole and nucleotide or nucleoside were carried out
at neutral pH, employing a monophasic reaction system with
acetonitrile as the co-solvent. Resulting reaction mixtures were
analysed by high performance liquid chromatography, UV spec-
trophotometry and electrospray mass spectrometry. Reactions with
all three N-nitrosoindoles gave rise to the same profile of
nucleotide or nucleoside modifications with the products
exhibiting a dose–response relationship. Depurination to guanine
and adenine was evident, as was deamination coupled with depuri-
nation, resulting in xanthine and hypoxanthine as the major
products. The formation of 2¢-deoxyoxanosine-5¢-monophosphate
and the depurination product oxanine was observed for reactions
with dpG, and oxanine was observed with dGuo. In addition,
N-acetyl adducts were evident, the source of acetyl groups being
the co-solvent. Analogous products were seen when incubations
were completed with 3¢-monophosphates. Denitrosation was the
major decomposition pathway of the nitrosated indoles in this
system. These findings combined with identical reaction products
for all nitrosated indoles and a positive result in the Liebermann
nitroso test at neutral pH suggests transnitrosation as the main
reaction pathway. In conclusion, these results indicate that
N-nitrosoindoles do not modify DNA through alkylation. Instead
they appear to mimic a nitric oxide type chemistry and undergo
N-N heterolytic cleavage to transfer the nitroso group to purine
bases resulting in deamination, depurination and the formation of a
novel product oxanine, all of which are potentially mutagenic
events.
Support from Glaxo-Wellcome is gratefully acknowledged.
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P4 Detection of malondialdehyde-deoxyguanosine in
white blood cells of volunteers on standardized diets
C Leuratti1, R Singh1, E Deag1, R Hughes2, S Bingham2, 
E Griech1, LJ Marnett3 and DEG Shuker1
1MRC Toxicology Unit, University of Leicester, UK; 2Dunn Nutrition Centre,
Cambridge, UK; 3Vanderbilt University, Nashville, TN, USA
DNA adducts can be formed upon exposure of DNA to both
exogenous and endogenous genotoxic agents. Malondialdehyde
(MDA) is an endogenous product of lipid peroxidation and
prostaglandin biosynthesis. The main adduct formed with DNA,
MDA-deoxyguanosine (M1-dG) has been detected in human
tissues and leucocytes. The aim of our work is to conduct a series
of studies in both volunteers and free-living populations in order to
examine whether diet modulates M1-dG formation in humans.
Dietary studies are being carried out with male volunteers housed
in the metabolic suite of the Dunn Nutrition Centre where diet can
be manipulated to desired levels. Initial results obtained by
HPLC/32P-post-labelling (Leuratti et al (1998) Toxicol Lett 95
(Suppl 1) 189) showed a tenfold increase in M1-dG levels in white
blood cell (WBC) DNA of two individuals on a red meat diet
compared to a free diet period. Introduction of vegetables and
black tea significantly reduced those levels. More recent results
using an immunoslot blot assay (Leuratti et al (1998)
Carcinogenesis 11: in press) confirmed a possible effect of a red
meat diet on M1-dG adduct levels which increased from unde-
tectable (free diet) to 10.05 (red meat) adducts per 107 normal
deoxynucleosides. Presently, DNA samples from WBC of volun-
teers maintained on a high meat diet for 40 days are being analysed
in order to examine possible time effects on M1-dG levels. Blood
samples are being collected at 5-day-time intervals. Results
obtained so far showed M1-dG levels ranging from 2.4 to 10.8
adducts per 107 deoxynucleosides.
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free-living populations for which samples have been collected
and dietary information are available through EPIC (European
Prospective Investigation on Cancer). Before carrying out analysis
on these samples, a detailed knowledge about the effect of long
term storage of samples on the stability of biomarkers of DNA
damage is required. In our laboratory, studies are ongoing on the
stability of M1-dG in blood samples stored for up to 5 years.
This study is funded by UK MAFF, contract no. FS1716 and
FS1735.
P5Risk assessment for liver cancer in women taking
tamoxifen
P Carthew, EA Martin, LL Smith, RE Edwards, RT Heydon
and BM Nolan
MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester
LE1 9HN, UK
Tamoxifen is a cumulative genotoxic hepatocarcinogen in the rat
(Carthew et al, 1995a) and, although most of the human carcino-
genicity associated with tamoxifen use has involved the uterus
(Van Leeuwen et al, 1994), it is still unclear whether tamoxifen
presents a possible long-term hepatocarcinogenic potential in
women. To clarify this possibility we have fed tamoxifen to rats
for differing periods of time (1–12 weeks) to induce increasing
amounts of DNA adducts in the liver. The dose–response relation-
ship between tamoxifen-specific DNA adduct formation and the
subsequent development of liver tumours over the next 2.5 years
has been examined to determine the nature of the dose–response
relationship. To increase the sensitivity of the bioassay groups of
tamoxifen-exposed rats were also given phenobarbital in the
drinking water to model a worst case scenario of liver cell prolifer-
ation and promote tumour formation (Carthew et al, 1995b). A
dose–response relationship was found for adduct levels and liver
tumour formation and a no effect level (NOEL) for tamoxifen-
induced liver tumours and DNA adducts was determined. The
comparison of this NOEL to the available data for adduct levels in
liver biopsies from women taking tamoxifen showed that a signif-
icant safety margin of approximately 100-fold exists between the
adduct levels in rats at the no effect level for liver tumours and the
levels of adducts found in women taking tamoxifen. This new
method of risk assessment based on the correlation of levels of
adducts known to be mechanistically related to subsequent cancer
formation in rodents with levels of the same adducts found in man
will be useful in further risk assessment for potential human
carcinogens.
REFERENCES
Carthew P et al (1995a) Carcinogenesis16: 1299
Carthew P et al (1995b) Cancer Res55: 544
Van Leeuwen FE et al (1994) Lancet343: 448
P6Ezrin regulates cell–cell adhesion and motility and
associates with intercellular junctional proteins in
cancer cells
S Hiscox, RE Mansel and WG Jiang
Department of Surgery, University of Wales College of Medicine, Cardiff
CF4 4XN, UK
Ezrin is a member of the ERM family of proteins that are thought
to function as cross-linkers between the plasma membrane and the
action cytoskeleton. Ezrin has also been implicated as playing a
role in intracellular signal transduction since both its tyrosine-
phosphorylation and translocation occurs in response to growth
factor receptor stimulation. Studies have shown that these proteins
can directly associate with cell surface adhesion molecules
including CD44 and ICAM2 and thus they may play a role in
mediating cell–cell adhesion. The aim of this study was thus to
investigate further the role of ezrin as a mediator of cell adhesion
and metastatic behaviour in colorectal cancer cells, HRT18 and
HT115.
Following experimental inhibition of ezrin expression within
these cells using anti-sense oligonucleotides, time-lapse video
microscopy demonstrated that both cell types showed a loss in
intercellular adhesions. HT115 cells, which lack E-cadherin, were
quickly dissociated following ezrin inhibition, whereas in HRT18
cells, which express E-cadherin and form tightly-packed colonies,
there was both a marked formation of intercellular gaps within
these colonies together with a movement of cells at the colony
edge away from the main colony body. These changes were
confirmed with transmission electron microscopy studies, which
showed a marked degeneration of the cell–cell junctions within
these cells after anti-sense treatment.
Induction of loss of ezrin expression with anti-sense oligonu-
cleotide also enhanced the motile and invasive capabilities of these
cells particularly following stimulation with HGF/SF, a potent
promoter of metastatic cell behavior, as shown by a phagokinetic
colloidal gold assay and basement membrane invasion assays
respectively.
Immunoprecipitation of ezrin from the cell lysates revealed that
in HRT18 cells, both b-catenin and E-cadherin co-precipitated
along with ezrin, whereas in HT115 cells which lacked E-cadherin
expression, ezrin was associated with the desmosomal cadherin,
Dsg.
In conclusion, these results show that removal of ezrin from
colon cancer cells results in dissociation of cell colonies together
with an enhancement of both their motile and invasive capabilities.
These effects are likely to be the consequence of loss of cell–cell
adhesion mediated by cadherin complexes, due to absence of
ezrin. These results thus implicate ezrin as a regulator of cadherin-
mediated adhesion and thus as a potential suppressor of tumour
cell motility and invasion.
P7Induction of apoptosis in the hepatoma-derived cellline, PLC/PRF/5, by g-linolenic acid
A Redfern and WG Jiang
Department of Surgery, University of Wales College of Medicine, Cardiff
CF4 4XN, UK
Essential fatty acids (EFAs) cannot be synthesized by the human
body and must therefore be obtained from the diet. In recent years,
certain EFAs, including g-linolenic acid (GLA), have been shown
to be selectively toxic to tumour cells. This study was designed to
investigate the mode of cell death in the cell line PLC/PRF/5
following treatment with GLA.
Extensive DNA cleavage, a characteristic feature of apoptosis,
was assessed by flow cytometry using a method based on the
extraction of low molecular weight DNA prior to cell staining.
This results in apoptotic cells containing a reduced DNA content
and therefore can be recognized as cells with low DNA stainability
which are seen as a sub G1/G0 peak. In addition, Western blotting
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of GLA concentrations (0–100 mM, 24 and 48 h). The membranes
were then probed with antibodies against Bcl-2 family members to
determine whether any changes occurred in their expression
following GLA treatment.
Flow cytometry data indicated that high levels of GLA (200 and
300 mM) induced apoptosis after 24 h of treatment. The percentage
of events below G1/G0 was, on average, 7.0% and 14.8% for
200 mM and 300 mM GLA, respectively, compared to a control
value of 2.8%. However, by 48 h apoptosis was induced in cells
treated with 100 mM GLA (on average, 5.3% compared to a control
value of 3.5%). Analysis of the cell cycle showed, at higher levels
of GLA, a slight trend towards a reduction in the population of
cells in G2/M and a concomitant increase in the population of cells
in S phase. This may suggest an arrest of the cell cycle in S phase.
Staining-treated cells with Hoechst 33528 confirmed the presence
of an increased number of apoptotic cells in samples treated with
GLA compared to control samples. Western blotting indicated that
Bcl-Xs, a Bcl-2 family member was present at low levels that
increased, over 24 h, with increasing GLA concentration.
However, no detectable level of Bcl-2 protein or its antagonist Bax
was observed. Additionally, Bag-1, a Bcl-2 binding protein was
detected, but no changes in expression were observed.
In conclusion, these data show that GLA induces apoptosis in
the hepatoma-derived cell line PLC/PRF/5, an effect, at least in
part, associated with changes in Bcl-2 family members, such as
Bcl-Xs.
P8 Effects of flavonoids on primary oral cultures:
enhanced sensitivity of tumour cells to growth
inhibition by morin
J Brown1, F McGregor1, J O’Prey1, E Wagner1, D Felix2,
D Soutar3 and PR Harrison1
1The Beatson Institute for Cancer Research, CRC Beatson Labs, Glasgow
G61 1BD, UK, 2Department of Oral Medicine, Dental School, Glasgow
G2 3JZ, UK; 3Department of Plastic Surgery, Canniesburn Hospital,
Glasgow G61 1QL, UK
Flavonoids are chemopreventive in several chemically induced
animal cancer models and may be one of the components of fruits
and vegetables responsible for chemoprotective effects in humans.
The effects of eight naturally occurring flavonoids were investi-
gated on a panel of oral primary cultures derived from biopsies
from normal oral mucosa and oral lesions at various stages of
cancer progression, i.e. early dysplasias, late-stage tumours and
metastases. Cells were treated with flavonoids for 3 days and 3H-
thymidine incorporation was measured in the final 6 h. All the
flavonoids inhibited oral cell growth with IC50 values in the range
18–54 mM, but they did not show any stage specificity. However,
although higher concentrations of morin were required to inhibit
cell growth, it had significant tumour specificity (IC50 for tumour
and normal cultures 110 mM and 180 mM respectively). This
change in specificity occurred at the dysplasia stage of cancer
progression. Structure function comparisons with other flavonoids
showed that the tumour-specific effect of morin required both the
2¢ and 4¢ hydroxyl groups. Further studies with quercetin and
morin have shown that they inhibit the growth of oral carcinomas
in the G2/M phase of the cell cycle, with no evidence of apoptosis
at these growth inhibitory concentrations.
Flavonoids are known to inhibit various signalling enzymes
involved in cell growth. We are presently testing candidate
enzymes which may be inhibited by flavonoids and which may be
activated during cancer progression. We have shown that the
growth inhibitory effect of quercetin but not morin can be reversed
by the addition of the lipoxgyenase metabolites 5-, 12- and 15-
HETEs, suggesting that the lipoxgyenase signalling pathway is
involved the growth inhibitory effects of quercetin. In addition, we
have found that activation of the stress kinase pathway may be
involved in the growth inhibitory effect of morin.
P9 Cytochrome P450 CYP1B1 in breast cancer
GI Murray1, S Buchan1, MCE McFadyen1, ID Miller1, 
S Payne1 and WT Melvin2
Departments of 1Pathology, 2Molecular and Cell Biology, University of
Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
Cytochrome P450 CYP1B1 is the only known member of a
recently identified sub-family of the cytochrome P450 CYP1 gene
family. We have previously shown increased expression of
CYP1B1 in several types of human cancer. Human CYP1B1
expressed in yeast shows high specific activity towards the 4-
hydroxylation of 17b-oestradiol converting it to 4-hydroxyoestra-
diol, while there is significant 4-hydroxylation of oestradiol in
breast cancer. In this study we have developed monoclonal anti-
bodies to human CYP1B1 and used these antibodies to investigate
the expression of CYP1B1 by immunohistochemistry in a series of
primary breast cancers. The monoclonal antibodies were gener-
ated using a synthetic peptide coupled to carried protein as the
immunogen. Hybridoma clones were initially screened using
peptide conjugate, and positive clones were then also tested for
recognition of human CYP1B1, which had been expressed in
lymphoblastoid cells. The monoclonal antibodies specifically
recognized CYP1B1 and the antibodies did not recognize either
expressed CYP1A1 or CYP1A2. CYP1B1 was not detected in
several normal tissues including liver, lung, small intestine and
kidney. The monoclonal antibodies were also tested by immuno-
histochemistry using sections of a breast cancer, which we have
previously shown to contain a high level of CYP1B1. One of the
antibodies was found to be effective by immunohistochemistry on
formalin-fixed, wax-embedded tissue sections and was used in the
subsequent immunohistochemical studies. The majority of breast
cancers showed positive immunoreactivity for CYP1B1 and
CYP1B1 was specifically localized to tumour cells. The presence
of CYP1B1 in breast cancer cells is likely to contribute to their
metabolism of oestradiol and CYP1B1 also provides a molecular
target for anticancer drugs specifically activated by this form of
P450.
This research has been supported by a grant from the Medical
Research Council.
P10 Expression of hypoxia-inducible factor-1a and
vascular endothelial growth factor in glioblastoma
multiforme
KL Søndergaard1, D Hilton2 and AG Demaine1
1Department of Molecular Medicine, Plymouth Postgraduate Medical School,
Plymouth PL4 8AA, UK; 2Department of Histopathology, Derriford Hospital,
Plymouth PL6 8DH, UK
Hypoxia-inducible factor-1 alpha (HIF-1a) is a transcription factor
that stabilizes wild-type p53 and is widely expressed in tissues
under hypoxic conditions. HIF-1a transcriptionally activates
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critical role in the expression of genes involved in angiogenesis.
Although VEGF is known to be up-regulated in many tumours
including glioblastoma multiformes (GBM), at present little is
known about the mode of expression of HIF-1a. The aim of this
study was to investigate the expression of HIF-1a, as well as
VEGF and p53, in 25 GBM samples using RT-PCR and immuno-
cytochemistry. Out of the 25 tumour samples, 20 (80%) expressed
HIF-1a, 21 of the 25 (84%) expressed VEGF and 16 of the
25 (64%) tumour samples displayed overexpression of p53 (> 20%
labelling). Of the 20 HIF-1a-positive samples, 13 (65%) displayed
overexpression of p53, with three of the five (60%) HIF-1a-
negative tumours displaying overexpression of p53. Only one of
the five (20%) HIF-1a-negative tumours was also VEGF-nega-
tive. VEGF expression varied from 1- to 100-fold (mean 25-fold)
in all of the GBM tumour samples. All GBM tumour samples
displayed similar degrees of necrosis and vascular proliferation.
This study did not find a correlation between HIF-1a expression,
VEGF expression, overexpression of p53, tumour vascularity or
necrosis.
P11 The profile of MHC antigen expression in normal
and leukaemic B-cells in patients with choronic
lymphocytic leukemia (CLL)
AME Nouri, Z Entezami, M Macey and RTD Oliver
Department of Medical Oncology, Royal London Trusts, London E1 1BB, UK
This study was set up to investigate the profile of MHC class I and
class II antigens in CLL patients using flowcytometric analysis.
In total 13 patients were used, most of whom have had no prior
treatment.
The results can be summarized as follows:
1. All CD5-negative cells expressed class I and class II antigens.
The per cent of cases positive for polymorphic HLA-Bw6,
-Bw4, -B7, -A2 and -B27 antigens were 84, 46, 15, 23 and 7
respectively.
2. In all the cases, Vim (antibody-specific for fibroblast and
used as a negative control) and transferrin receptor showed
negativity on CD5-negative cells.
3. The ratios of class II antigens for CD5-positive/CD5-negative
cells were more than one in all cases except three (cases 2, 3
and 6). Similar results were observed for 12 of 13 cases for
monomorphic class I (except case no. 5) antigens, whilst in the
case of polymorphic class I antigens all the values were above
unity.
4. Similarly, in all cases, the ratios for CD71 were above unity.
These results clearly indicated that, unlike solid tumours where
the loss of class I antigens (particularly those detected by polymor-
phic-specific antibodies) is a frequent event, in CLL leukaemic
patients this is not the case. That is to say, the loss or abnormal
expression of these antigens does not play an important role in
CLL malignancy. The overexpression of class II antigens on CD5-
positive compared with CD5-negative cells is interesting, and
experiments are in progress to assess the significance of this
observation.
P12 Interferon  a and its various functional facets in
comparison with other cytokines in an in vitro setting
AME Nouri, ST Zubairi and RTD Oliver
Royal London Trusts, London, UK
The clinical efficacy of interferon alpha (IFN-a), and to a lesser
extent other cytokines, is well established. Using various tech-
niques the biological activities of recombinant IFN-a as well
as IFN-g and an in-house prepared mix of cytokines or active
supernatant (AC) were investigated.
Results showed that:
1. Whilst both IFN-a and AC up-regulated MHC class I antigens,
class II antigens were only induced by AC. These results were
also demonstrable for intracellular cell adhesion molecule
(ICAM-1). Thus, the mean ± s.d. of radiobinding values for
seven tumour lines for untreated, IFN-a and IFN-g-treated
cells were 617 ± 406, 943 ± 471 (P = 0.001) and 702 ± 563
(P > 0.05) cpm respectively.
2. Both IFN-a and AC increased the killing activity of IL-2-
activated mononuclear cells (LAK) cells by as much as 15%.
In addition, pretreatment of tumour target cells with IFN-a
increased their susceptibility to killing by as much as 25%.
3. IFN-a and AC showed direct cytotoxic effects on some
tumour cell lines like Wil (a bladder line) by as much as 36%.
4. Combination of IFN-a and cisplatin showed additive suppres-
sive effects on tumour lines. In addition, tumour cell lines
exposed to AC and cisplatin showed that, whilst the expression
of inducible molecules like class II was severely decreased,
there was only a modest inhibition of class I,
EGFr and p53 molecules.
The findings of this investigation demonstrated the capacity of
IFN-a to increase the visibility of tumour cells to the immune
system by increasing the expression of MHC class I antigens. The
data also demonstrated that IFN-a acted at other levels
contributing to its overall clinical efficacy.
P13 The evolution of LOH on chromosome 17 during
the progression to Barrett’s adenocarcinoma
J Garde1, J Dunn1, K Dolan1, J Gosney2, R Sutton3 and 
JK Field1
1Molecular Genetics and Oncology Group, Clinical Dental Sciences,
2Department of Pathology, 3Department of Surgery, The University of
Liverpool, Liverpool L69 3BX, UK; 4Department of Surgery, Thameside
General Hospital, Fountain Street, Ashton Under-Lyne, Greater Manchester
OL6 9RW, UK
We have previously identified 13 common, minimally deleted
regions (MRs) on chromosome 17 in 12 Barrett’s oesophageal
adenocarcinoma (BOA) specimens using multiple precisely
mapped microsatellite markers (Dunn et al (1999) Oncogene, in
press). The aim of the present study has been to identify the
earliest sites of loss on this chromosome that arise and persist
during the progression to BOA. This has been undertaken by the
analysis of multiple carefully micro-dissected tissue samples from
each of five oesophagectomy specimens, several of which 
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step-wise accumulation of loss in each analysed specimen, consis-
tent with a single clonal pathway in four specimens and several
coexisting pathways in one specimen. Several clonal anomalies
(loss preceding heterozygosity, and variable intra-sample degrees
of loss at different markers) were also observed. Within exten-
sively deleted regions of the tumour (seen in three specimens),
small deletions were detected in earlier tissue, predominantly at
the site of our identified MRs, and these losses were seen to
expand and merge during the progression to BOA. Some clonal
losses at MRs were first detected in histologically early tissue,
including metaplastic columnar epithelium, squamous epithelium
and dysplasia. Our results provide further support for many of the
MRs we have previously identified, thereby adding to evidence of
the existeance of multiple novel tumour suppressor genes on chro-
mosome 17 involved in the development of BOA.
P14 Heat shock protein (Hsp) expression in ascitic
ovarian cancer cells and related resistance to cytotoxic
killing by lymphocytes
X Han, B Kelly, GD Wilbanks, O Devaja and K Raju
Department of Obstetrics & Gynaecology, St Thomas Hospital, London, UK
It is well known that heat shock proteins (Hsps) protect cells from
a number of injurious factors (Lindquist (1988) Annu Rev Genet
22: 631). Our previous study showed that co-culture of ascitic
ovarian cancer cells with IL-2-activated lymphocytes induced
immunoresistance of the ovarian cancer cells to immunocyto-
toxicity (Papadoupoulos et al (1995) Gynecol Oncol 57: 388). This
implies that hsp expression may play an important role in the
mechanisms leading to this form of immunoresistance. The aim of
this study was firstly to investigate HSP expression within ovarian
cancer cells in vivo in ascites and in vitro in co-culture, and
secondly to observe if immunoresistance was related to HSP
expression.
Tumour/lymphocyte co-culture was used to induce immuno-
cytotoxic (ICT) stress to ovarian cancer cells isolated from malig-
nant ascites. Immunocytochemistry (ICC) using a panel of
antibodies against Hsp27, 60, 70 and 90 was employed to detect
hsp expression. 51Chromium-release cytotoxicity assay was used
to evaluate resistance/sensitivity of ovarian cancer cells to
lymphocyte mediated-cytotoxicity.
Freshly isolated ovarian cancer cells from ascites exhibited
expressions of Hsp60, Hsp70 and Hsp90 in a variable range as
tested by ICC. After co-culture with activated lymphocytes. ICT-
stressed ovarian tumour cells exhibited overexpression of Hsps,
predominantly Hsp90, tested by ICC. In 51Chromium release
cytotoxicity assays, we found that ICT stressed ovarian cancer
cells, which expressed HSPs, were resistant to IL-2 activated
lymphocyte-mediated cytotoxicity. We also noticed a non-MHC
restricted feature of this resistance as autologous lymphocyte
stressed-tumour cells resist allogenic lymphocyte-cytotoxicity.
Data from our experiments demonstrate that Hsps expression
can be found in vivo within ascitic ovarian cancer cells and also
can be induced by in vitro ICT-stress. Such expression may be
involved in resistance of tumour to cytotoxicity mediated by
immune-competent cells. The clinical significance of this study
lies in the possibility of opening a new avenue in the
immunotherapy of ovarian cancer with alteration of Hsp gene
expression by anti-sense treatment to augment immuno-
cytoxicity mediated by immune-competent cells.
REFERENCES
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P15 Modulation of P-glycoprotein expression in
ribozyme-transfected multidrug resistant (MDR) lung
tumour cells
EL Lewis1 and I Gibson2
1University of East Anglia, School of Biological Sciences, Norwich NR4 7TJ,
UK; 2House of Commons, Westminster, UK
Overexpression of the MDR1 gene and its translation product, the
trans-membrane energy-dependent efflux pump (Pgp: 170 kDa), is
one of the major mechanisms by which cancer cells develop the
MDR phenotype. The up-regulation of Pgp results in the prema-
ture expulsion of a variety of amphiphilic cytotoxic drugs and is a
major impediment to successful chemotherapy (reviewed by
Germann (1996) Eur J Cancer 32A: 927). Efforts to reverse the
Pgp-based MDR phenotype have focused principally on agents
which are competitive inhibitors of the Pgp pump, or gene
targeting (Bouffard et al (1996) Eur J Cancer 32A: 1010). In order
to reduce Pgp levels in MDR small-cell lung cancer cells, NIH
H69/LX4, we have constructed recombinants for the exogenous
(pFORTH: Tabler and Tsagris (1991) Gene 108: 175) and endoge-
nous (pHBetaAprl-neo: Gunning et al (1987) Proc Natl Acad Sci
USA 84: 4831) synthesis of long-chain asymmetric hammerhead
ribozymes (catalytic anti-sense RNAs) targeting the regions of
MDR1 mRNAs predicted to have a low folding potential (Sczakiel
et al (1993) Antisense Res Dev 3: 453) and/or conserved sequences
(Lewis and Gibson (1997), BACR 38th Annual Meeting, Abstract
P57: 33)
Ribozymes and substrates for in vitro analyses were transcribed
from the recombinant pFORTH vector-encoded T7 or T3
promoter, respectively, using Ampliscribe (Cambio). The catalytic
activity of the ribozymes were assessed by electro-separation of
the cleavage products through denaturing gels (Separide, Life
Technologies). Constitutive expression of a ribozymes directed to
exons 20 and 21 MDR1 mRNA sequences in stably- (500 µg ml–1
G418 selection) and transiently-liposome-transfected (Lipo-
fectAmine, Life Technologies) NIH-H69/LX4 cells resulted in a
significant reversal of their resistance profile. The relative toxicity
of the Pgp substrate doxorubicin (PNNAG Assay), expressed as
LD50 was reduced to parental (NIH H69/P) levels. The amplitudes
of inhibition of MDR1 mRNA relative to b-actin (slot blotting) in
NIH H69/LX4 cells expressing the ribozyme transiently- or stably
were 27–37% or 80% respectively, concomitant with modulation
of Pgp expression (Western immunoblotting: mAb C219) and
~60–78% increase in drug accumulation. The phenotype of the
control cells (untreated, LipofectAmine-treated or expressing the
vector alone) was vitually unaltered.
This work is supported by The Big C Appeal, Mrs P Salter,
Francesca Gunn Leukaemia Appeal and AICR.
582 Abstracts of preferred papers
British Journal of Cancer (1999) 81(4), 565–585 © 1999 Cancer Research CampaignP16 Synergistic action of Temozolomide and
thioguanine on glioblastoma xenografts
DC Sullivan and PF Swann
Biochemistry and Molecular Biology, University College London, London
WC1E 6BT, UK
It has been proposed that the cytotoxic action of thioguanine
involves the following steps: (1) thioguanine is incorporated
into DNA; (2) S-adenosylmethionine methylates it to form
S6-methylthioguanine; (3) recognition of base pairs containing
S6-methylthioguanine by proteins of the post-replicative mismatch
repair pathway leads to cell death (Swann et al (1996) Science 273:
1109). The mechanism of Temozolomide, a methylating agent
being used for the treatment of brain tumours, exactly parallels that
of thioguanine: it methylates guanine to form O6-methylguanine,
then base pairs containing this base are recognized by proteins of
the post-replicative mismatch repair pathway. Temozolomide
would also methylate the thioguanine so, if the mechanism
proposed for thioguanine were correct, one would expect a strong
synergism between the two drugs. To test a combination of
thioguanine and Temozolomide, a globlastoma (U87MG) was
transplanted into nude mice. Seven days later (a.v. vol of tumour
about 200 mm3) the mice were given thioguanine (i.p., 4 mg kg–1
day–1; 4 days). Eight hours after the fourth injection the mice were
given 5 mg kg–1 Temozolomide (i.p.). There was essentially no
difference between the control group and groups treated with
thioguanine alone, or with Temozolomide alone. In all three cases
the tumours reached 1000 mm3 between 7 and 8 days after begin-
ning the thioguanine treatment (i.e. 14 days after transplant).
However, the tumours in mice treated with both Temozolomide
and thioguanine were strongly affected and did not reach 1000
mm3 until 18 days (i.e. 25 days after transplant).
As Temozolomide produces O6-methylguanine there is an
inescapable chance that its use will cause cancer. Increasing the
effectiveness of Temozolomide by inhibiting O6-alkylguanine-
DNA-alkyltransferase (Wedge and Newlands (1996) Br J Cancer
73: 1049) will increase that risk. Thus the alternative of increasing
the effectiveness of Temozolomide by pretreatment with thio-
guanine may be a preferable course of action.
P17 Mismatch repair protein expression in response to
treatment with cisplatin
A Coupe, M Burgess, A Hancock and M Mott
Institute of Child Health, Royal Hospital for Sick Children, St Michael’s Hill,
Bristol BS2 8BJ, UK
Cisplatin induces DNA adducts, which are recognized by proteins
of the mismatch repair system. Loss of these proteins is implicated
in the development of resistance. This occurs either directly due to
failure to recognize damaged DNA or indirectly by permitting
mutational events in unrelated genes which in turn confer resis-
tance. Evidence supports the former and suggests a role for the
mismatch repair system in initiating apoptosis. The aim of this
study was to determine if the expression of hMSH2, hMLH1, and
hPMS2 protein altered in response to cisplatin exposure and to
determine the relationship, if any, to that of p53 and p21.
Following continuous exposure to cisplatin, protein lysates were
prepared from a variety of mismatch proficient and deficient cell
lines. Cells were harvested at either defined intervals over 24 h
following an IC75 dose of cisplatin or at 24 h following a
dose–response. Apoptosis was determined by propidium iodide
staining and flow cytometry. Protein levels were identified by
Western blotting and chemiluminescent detection and subsequent
densitometry. Cisplatin-induced apoptosis was demonstrated for
all cell lines. Increasing p53 and p21 protein levels were found in
all mismatch-deficient and proficient cell lines with respect to
cisplatin dose and time of exposure reaching a maximum at 16–
24 h. Conversely, the levels of MSH2, MLH1 and PMS2, where
present, remained unaltered. This indicates that in contrast to p53
and p21, whole cell levels of hMSH2, hMLH1, and hPMS2 are
independent of cisplatin damage.
P18 Effect of tumour size and tumour type on passive
tumour accumulation of polymeric anticancer agents
YN Sat1, M Bibby2 and R Duncan1
Centre for Polymer Therapeutics, School of Pharmacy, 29–39 Brunswick
Square, London WC1N 1AX, UK; 2University of Bradford, Bradford, UK
Tumour vasculature differs from normal vessels in that the
endothelium is frequently discontinuous and it lacks a basement
membrane (Jain, 1987). The resultant selective extravasation of
circulating soluble macromolecules (polymers and proteins) and
liposomes affords a means to target drugs selectively to solid
tumours by a mechanism termed ‘enhanced permeability and
retention’ (EPR) effect (Matsumara and Maeda, 1986; Duncan
et al, 1996). Due to the known inherent differences in tumour
vasculature of different tumour types, and also different vasculari-
zation states at different stages of tumour development, it is
important to calibrate experimental tumour models according to
their capacity to capture macromolecules by the EPR effect.
Understanding the EPR effect is also vitally important in the
context of targeting molecular medicines, e.g., gene therapy. Here,
HPMA copolymer-doxorubicin (PK1) and Evans blue dye were
used as probes to define the EPR effect in different tumour types
(murine and human tumour xenografts) and tumours of different
size at 1 h after intravenous administration.
In B16F10 murine melanoma, total PK1 accumulation was
highest when the tumour size was smallest (13.7 ± 3.6 % dose g–1,
< 0.1 g). Accumulation decreased as tumour size increased
(1.1  ± 1.0 % dose g–1 > 1 g). Using Evans blue as probe, a similar
accumulation pattern was observed in the small and large tumours
respectively (16.5 ± 9.5 % dose g–1, <0.1 g; 2.7 ± 0.9 % dose g–1,
>0.9 g). In MAC 15A and MAC 26 models there was no difference
in tumour accumulation of PK1 with increasing tumour size and
uptake was 8–11 % dose g–1). In human tumour xenografts, PK1
displayed highest accumulation in a SK-N-SH (8.1 ± 2.9 % dose
g–1), followed by COR L23 (7.8 ± 1.1 dose % g–1) and then SK-N-
DZ (3.3–3.7 % dose g–1). In addition to displaying different
degrees of PK1 uptake, the tumours displayed different capacities
to release free doxorubicin from the conjugate (doxorubicin
release is mediated by lysosomal thiol proteases). Extent of
polymer capture by the EPR effect, and differences in intra-
tumoural enzyme level would be expected to effect anti-tumour
activity and hence the clinical outcome.
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source of DNA damage in man
KL Harrison1,2 and DEG Shuker1
1MRC Toxicology Unit, University of Leicester, Leicester LE1 9HN, UK;
2School of Epidemiology and Health Sciences, University of Manchester,
Manchester M13 9PT, UK
Raised levels of alkyl-DNA adducts have been associated with
increased risk of cancers in man. In particular, O6-methylguanine
(O6-MG) is elevated in DNA from individuals at high risk of GI
tract cancers. Recently we have shown that nitrosated glycine
derivatives such a N-nitrosoglycocholic acid gives rise to O6-MG
(Shuker and Margison, Cancer Res (1997) 57: 355) as well as the
expected  O6-carboxymethylguanine (O6-CMG), (Harrison et al
(1997)  Chem Res Toxicol 10: 652). O6-CMG is a useful marker of
nitrosated glycine derivatives and a sensitive immunoslot blot
method has been developed for use in experimental and human
studies. Administration by gavage of potassium diazoacetate
(nitrosated glycine) to rats resulted in dose-dependent and persis-
tent increases in O6-CMG in stomach DNA. O6-CMG was
detected in untreated animals at a level of 20 O6-CMG 10–7 G.
Interestingly, O6-CMG was also detected at similar levels in both
gastric DNA (18–104 adducts 10–7 G) and peripheral lymphocyte
DNA (6–250 adducts 10–7 G) from patients attending a dyspepsia
clinic (in collaboration with Prof. ATR Axon and Dr S Everett,
Centre for Digestive Diseases, Leeds General Infirmary, Leeds).
Taken together, the detection of increased levels of O6-CMG
adducts in stomach DNA from experimental animals exposed to
potassium diazoacetate and the detection of the same adduct in
both unexposed animal and human gastric DNA suggests that
nitrosated glycine derivatives may be the responsible agents.
Funding from the Medical Research Council and MAFF is
gratefully acknowledged.
P20 Highly sensitive and rapid immunoassay for
the quantitation of imidazole ring opened
N7-methyldeoxyguanosine in human DNA
K Harrison1,2, K Haque1, GP Margison1 and AC Povey2
1Department of Genome Damage and Repair, CRC Paterson Institute,
Manchester M20 9BX, UK; 2School of Epidemiology and Health Sciences,
Manchester University, Manchester M13 9PT, UK
N7-methyldeoxyguanosine (N7-medGua) could be a useful
biomarker of recent past exposure to environmental and endo-
genous methylating agents for use in epidemiological studies
(Saffhill et al (1985) Biochem Biophys Acta 832: 111). In order
to investigate the presence of N7-medGua in human samples
obtained from routine surgical biopsies it is necessary to have a
sensitive assay system that requires the minimum amount of DNA
(< 10 mg). To this end polyclonal antibodies against the chemically
stabilized imidazole ring-opened form of N7-medGua (RON7-
medGua) have been used to develop a highly sensitive immunoslot
blot assay adapted from a method by van Delft et al ((1994)
Carcinogenesis 15: 1867).
DNA which had been methylated in vitro with N-methyl-N-
nitrosourea was used to generate a standard of known N7-
methyldGua concentration as determined by 32P-post-labelling
(Haque et al (1994) Carcinogenesis 15: 2485). This was then
diluted with various amounts of unmethylated calf thymus DNA to
generate a series of standards. The immunoslot blot assay afforded
a limit of quantitation of 0.097 mmol RON7-medGua/mol
deoxyguanosine (dGua) using only 1 mg per analysis enabling
samples to be run in duplicate or triplicate on at least one occasion.
Method validation was carried out on pyloric DNA of rats
treated with N-methyl-N´-nitro-N-nitrosoguanidine, for which
N7-medGua levels had already been quantitated by
32P-post-labelling. The results showed a high degree of correlation
between the two assays (r = 0.99). N7-medGua was analysed in
DNA samples contaminated with known amounts of RNA to
investigate the possible interference of 7-methylguanosine, which
is a naturally occurring minor nucleoside in RNA (Bianchini et al
(1993) Carcinogenesis 14: 1677). Up to 0.5 mg RNA 1 mg–1 DNA
did not result in an increased background signal. The immunoslot
blot assay was then applied to a range of human DNA samples of
individuals not known to be exposed to methylating agents. Levels
of N7-medGua where detected in the range of 0.107–1.34 mmol
RON7-medGua/mol deoxyguanosine in bladder tumour, colon
carcinoma and colorectal mucosa DNA samples.
This rapid technique allowing for up to ten samples in tripli-
cate to be run on each blot should enable the determination of
the extent of human exposure to both environmental (diet) or
endogenous sources of methylating agents in normal colorectal
tissues.
P21 Inhibition of cell division and induction of
apoptosis in melanoma cells by a mycobacterial cell
wall complex
MC Filion, I Ménard, HE Phillips and NC Phillips
Bioniche Inc., 383 Sovereign Road, London, Ontario, Canada N6M 1A3 and
the Faculté de pharmacie, Université de Montréal, C.P. 6128, succursale
Centre-ville, Montréal, Québec, Canada H3C 3J7
Mycobacterial cell wall complex (MCC) is a cell wall composition
prepared from the non-pathogenic bacterium Mycobacterium phlei
where mycobacterial DNA is complexed on the cell wall surface.
We have previously shown that in addition to stimulating
macrophage cytokine synthesis, MCC inhibits the division of and
induces apoptosis in human bladder transitional carcinoma cells
(Filion et al (1998) Br J Cancer, in press). In this study we have
evaluated the ability of MCC to inhibit cell division and induce
apoptosis in melanoma cells. Adherent murine B16 melanoma
cells were treated with MCC for 24–72 h. Significant dose-depen-
dent inhibition of cell division (determined by the reduction of
MTT) was observed in the dose range 0.1–100 mg ml–1 MCC. No
direct cytotoxicity (determined by the release of the cytoplasmic
enzyme lactate dehydrogenase into the culture medium) was
observed following MCC treatment. Flow cytometric analysis
using propidium iodide showed that inhibition of cell division was
associated with an accumulation of cells at the S to G2 transition
phase of the cell cycle. Interleukin-1b-converting enzyme
(ICE/caspase-1), a cysteine protease involved in the sequential
activation of the caspase cascade required for apoptosis, is rapidly
and transiently activated by various pro-apoptotic stimuli.
Incubation of B16 melanoma cells with MCC resulted in a signifi-
cant dose-dependent increase in the level of ICE/caspase-1 activity
(determined using the fluorogenic substrate Z-Tyr-Val-
Ala-Asp[OMe]-7-amino-4-methylcoumarin) 3 h post-treatment.
Analysis of B16 melanoma DNA by agarose gel electrophoresis
following MCC treatment showed the presence of a 180–200 base
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chemotherapeutic-like activity by inhibiting the division of B16
melanoma cells in the absence of immune effector cells. The
observation that inhibition of cell division is associated with
ICE/caspase-1 activation and results in DNA fragmentation char-
acteristic of apoptosis indicates that MCC-containing formulations
may have application in the treatment of malignant melanoma.
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